Conjugates, compositions and methods for hydroxyapatite targeted imaging and treatment

Through the conjugate targeting hydroxyapatite, drugs and radioactive agents are delivered to the bones, which solves the problems that are difficult to achieve in the prior art drugs and improves the efficacy and imaging effects of bone disease treatment.

CN119072485APending Publication Date: 2024-12-03PURDUE RES FOUND
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380035705.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-02-24
Filing Date
2023-02-24
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

The prior art is difficult to effectively deliver drugs to bones, resulting in low efficiency in treatment of bone diseases and side effects of systemic treatment, especially the poor treatment effect of bone cancer, which cannot effectively eradicate or reduce tumor growth.

Method used

A conjugate targeting hydroxyapatite has been developed, including polyanionic ligands, polyacid ligands and/or polyelectrolyte ligands that bind hydroxyapatite, and radiographic agents, radiosensitizers or radioactive radiation The therapeutic agent, coupled to these active agents through a specific linker, is used for targeted bone delivery.

Benefits of technology

It realizes efficient delivery of drugs to bones, improves the efficacy of bone disease treatment, especially in the treatment of bone cancer, with significant imaging and treatment effects, reducing side effects on healthy bones.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119072485A_ABST
    Figure CN119072485A_ABST
Patent Text Reader

Abstract

Disclosed are conjugates targeting hydroxyapatite, compositions comprising the conjugates and methods for radioimaging or radiotherapy.
Need to check novelty before this filing date? Find Prior Art

Description

priority

[0001] This patent application is related to and claims the benefit of priority of U.S. Provisional Patent Application No. 63 / 313,395 filed on February 24, 2022. The contents of the above application are incorporated herein by reference in their entirety. Technical Field

[0002] The present disclosure relates to conjugates targeting hydroxyapatite, compositions comprising the conjugates, and methods of using such conjugates and compositions for imaging and therapy. Background Art

[0003] It is difficult to deliver drugs to the bone because its composition is different from that of other organs. It is mainly composed of calcium phosphate crystals called hydroxyapatite. Therefore, current systemic treatments are inefficient for various bone diseases because most of the drug is captured by internal organs and eventually excreted through the urine instead of concentrating in the diseased and damaged site. Increasing the dose can improve onsite targeting, but it also increases off-target systemic side effects. Therefore, effective bone-targeting systems are needed to improve the efficacy of drugs for bone diseases.

[0004] Among various bone diseases, bone cancer (e.g., bone metastasis due to breast or prostate cancer) has a particularly high mortality rate because current systemic chemotherapy and radiation therapy are ineffective in eradicating or reducing tumor growth. These treatments can only relieve pain induced by tumor-induced bone lesions at best, and therefore, many bone cancers are widely considered incurable. Therefore, it is urgent to develop bone-targeted therapies to improve patients' quality of life and survival. Summary of the invention

[0005] A conjugate of formula I is provided: HB-L A -A(Formula I) or a pharmaceutically acceptable salt thereof, wherein: HB is a group that binds to hydroxyapatite (e.g., linear or branched) polyanionic ligands, polyacidic ligands, and / or polyelectrolyte ligands (e.g., biological targeting moieties); A is a radioimaging agent, a radiosensitizer, a radioprotectant, or a radiotherapeutic agent; and L A is a linker that binds HB and A, or is absent.

[0006] HB may contain groups of linear polyanionic ligands, polyacidic ligands and / or polyelectrolyte ligands that bind hydroxyapatite. HB may contain amino acids or derivatives thereof. HB may contain L-aspartic acid, D-aspartic acid, L-glutamic acid, D-glutamic acid, or derivatives thereof, or a mixture of two or more of the above amino acids or derivatives thereof.

[0007] In some embodiments, HB may further comprise (i) a serum albumin binder (AB) directly conjugated to HB, or (ii) AB and a linker L. AB (AB-L AB ), where AB-L AB By L AB Conjugated to HB. In some embodiments, one or more peptide bonds of HB and / or A are arranged in a relative cis orientation. In some embodiments, one or more peptide bonds of HB and / or A are arranged in a relative trans orientation.

[0008] In some embodiments, L A , L AB or L A and L AB Both are L-configuration. In some embodiments, L A , L AB or L A and L AB Both are in D-configuration, and AB can be attached to the amino or carboxyl end of the polyacid peptide, or to the active group of the repeating anionic part, acidic part or electrolyte part of HB, such as carboxyl group, amine group or sulfhydryl group.

[0009] HB may contain a linear polyanionic group of formula X-A1, X-A2, X-A3 or X-A4 as shown below: in: R is COOH for L- or D-aspartic acid, CH2COOH for L- or D-glutamic acid, or CH2CH2COOH for an unnatural acidic amino acid; n = 1-50; Indicates that L A attachment point; and, When HB also contains AB or AB-L AB hour, Indicates AB or L AB attachment point.

[0010] In some embodiments, HB may not (e.g., does not) contain an albumin binder as shown in formula X-A3 and X-A4. HB may contain a branched polyanionic group of formula X-A5, X-A6, X-A7 or X-A8 as shown below: in: R is COO- for L- or D-aspartic acid, CH2COO- for L- or D-glutamic acid, or CH2CH2COO- for an unnatural acidic amino acid; n = 1-50; Indicates that L A Attachment point; When HB also contains AB or AB-L AB hour, Indicates AB or L AB attachment point; and represents the point of attachment to hydrogen or HB. In some embodiments, HB may not comprise an albumin binder such as shown in Formulas X-A7 and X-A8.

[0011] L A It may contain one or more amino acids. A May contain a brush border membrane (BBM) linker. A A BBM linker may be included which comprises Met-Val-Lys.

[0012] L A and L AB Either or both of L may include a slow-release linker. A May include slow release connectors. A May include quick release connectors. A Can contain L1 or L2 as shown below: in Indicates L A Between A and L A and the attachment point between HB.

[0013] L A and L AB Either or both of L may contain a spacer. A and L AB The conjugation may be to the N- or C-terminus of HB, to any monomer of its polymer, or to any substituent of any monomer of its polymer.

[0014] A may comprise a chelating agent. A may comprise DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) or a derivative thereof.A may be selected from the group consisting of: DOTA or its derivatives; TETA (1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid) or its derivatives; HEHA (1,2,7,10,13-hexaazacyclooctadecane-1,4,7,10,13,16-hexaacetic acid) or its derivatives; PEPA (1,4,7,10,13-pentaazacyclopentadecane-N,N',N",N"',N""-pentaacetic acid); SarAr (1-N-(4-aminobenzyl)-3,6,10,13,16,19-hexaazabicyclo[6.6.6]-eicosane-1,8-diamine) or its derivatives; NOTA (1,4,7-triazacyclononane -1,4,7-triacetic acid) or its derivatives; NETA (4-[2-(dicarboxymethylamino)-ethyl]-7-carboxymethyl-[1,4,7]triazacyclononane-1-yl)acetic acid or its derivatives; TRAP (1,4,7-triazacyclononane-1,4,7-tri[methyl(2-carboxyethyl)phosphinic acid) or its derivatives; HBED (N,N0-bis(2-hydroxybenzyl)-ethylenediamine-N,N0-diacetic acid) or its derivatives; 2,3-HOPO (3-hydroxypyridin-2-one) or its derivatives; PCTA (3,6,9,15-tetraazabicyclo[9.3.1]-pentadeca-1(15),11,13-triene-3,6,9-triacetic acid) or its derivatives PDTA (1,3-propylenediaminetetraacetate) or its derivatives; NTA (nitrilotriacetate) or its derivatives; EDDS (ethylenediamine disuccinate) or its derivatives; EDTA (ethylenediaminetetraacetic acid) or its derivatives; MGDA (N-(1-carboxyethyl)iminodiacetate) or its derivatives; DFO (deferoxamine) or its derivatives; DTPA (diethylenetriaminepentaacetic acid) or its derivatives; CDTA ((1,2-cyclohexylidenenitrilo)tetraacetic acid) or its derivatives; CPTA (1,4,8,11-tetraazacyclotetradecane derivative) or its derivatives; OCTAPA (N,N0-bis(6-carboxy-2-pyridylmethyl)-ethylenediamine-N,N0-diethyl acid) or its derivatives; H2-MACROPA (N,N'-bis[(6-carboxy-2-pyridylmethyl]-4,13-diaza-18-crown-6) or its derivatives; H2dedpa (1,2-[[carboxy)-pyridin-2-yl]-methylamino]ethane or its derivatives; HEDP (hydroxyethylidene diphosphonate or etidronate) or its derivatives; HEBD (N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid) or its derivatives; HYNIC (6-hydrazinopyridine-3-carboxylic acid) or its derivatives; DMSA (meso-2,3-dimercaptosuccinic acid) or its derivatives; and an EC20 head comprising β-l-diaminopropionic acid, Asp and Cys.

[0015] The chelating agent can chelate alpha emitting radioisotopes, such as 225 Ac. The chelating agent can chelate beta-emitting radioisotopes, such as 177 Lu or 90 Y. The chelating agent may chelate gamma-emitting radioisotopes, such as 111 In or 67 Ga. The chelating agent can chelate 18 F. 44 Sc, 47 Sc, 52 Mn, 55 Co. 64 Cu, 67 Cu, 67 Ga, 68 Ga, 86 Y. 89 Zr, 90 Y. 99m Tc, 111 In, 114m In, 117m Sn, 124 I. 125 I. 131 I. 149 Tb, 153 Sm, 152 Tb, 155 Tb, 161 Tb, 177 Lu, 186 Re, 188 Re, 212 Pb, 212 Bi, 213 Bi, 223 Ra, 224 Ra, 225 Ab. 225 Ac or 227 Th.

[0016] A may comprise a chelating agent that chelates or binds a radioisotope. The radioisotope may be a therapeutic radioisotope. The radioisotope may be a positron emission tomography (PET) imaging radioisotope (e.g. 68 Ga) or choose 11 C. 13 N. 15 O and 18 The radioisotope may be a therapeutic radioisotope, including an alpha-emitting radioisotope or a beta-emitting radioisotope. In certain embodiments, the beta-emitting radioisotope is 177 Lu.

[0017] The chelating agent can be an imaging radioisotope or a PET imaging radioisotope. In certain embodiments, the imaging radioisotope is a gamma emitting radioisotope and is 111 In.

[0018] A can include the following 14 C. 3 H. 34 S. 32 P. 125 I and 131 I. The radioactive reagent A can be connected by a linker L A Conjugated to the N- or C-terminus of HB, or to any reactive group on the HB repeating portion.

[0019] The conjugate may have the following structure:

[0020] The conjugate may have the following structure:

[0021] The conjugate may have the following structure:

[0022] The conjugate may have the following structure:

[0023] The conjugate may comprise 177 Lu-chelated conjugate having the structure:

[0024] The conjugate may comprise 111 In chelated conjugate having the structure:

[0025] Also provided is a pharmaceutical composition. The pharmaceutical composition comprises a conjugate of Formula I or Formula IA, or a pharmaceutically acceptable salt of Formula I or Formula IA, and a pharmaceutically acceptable carrier or excipient. The pharmaceutical composition may also comprise a radiosensitizer, a radioprotectant, an immunotherapeutic agent, a chemotherapeutic agent, an anticancer agent, and / or a hormonal therapeutic agent.

[0026] A method for imaging and / or treating a subject's bones is also provided. In certain embodiments, the method comprises administering to the subject an effective amount (e.g., a therapeutically effective amount) of the following substances: (i) a conjugate described herein or a pharmaceutically acceptable salt thereof, the first pharmaceutical composition described herein (e.g., comprising the conjugate or a pharmaceutically acceptable salt thereof), or (ii) a first pharmaceutical composition comprising a conjugate of Formula I or IA and a first pharmaceutically acceptable carrier or excipient, simultaneously or sequentially, in either order, (b) (i') an active agent (e.g., a free drug), or (ii') a second pharmaceutical composition comprising the active agent and a second pharmaceutically acceptable carrier or excipient. The active agent of (b) may be / comprises a radiosensitizer, a radioprotectant, an immunotherapeutic agent, a chemotherapeutic agent, an anticancer drug, or a hormonal therapeutic agent. The active agent of (b) may comprise lysine (Lys).

[0027] The subject may have cancer, such as a primary bone cancer (e.g., osteosarcoma, chondrosarcoma, Ewing sarcoma, or chordoma) or a secondary bone cancer (e.g., metastatic breast cancer, prostate cancer, multiple myeloma, thyroid cancer, lung cancer, kidney cancer, ovarian cancer, colon cancer, or melanoma).

[0028] The method may further comprise imaging the subject's skeleton. When imaging the subject's skeleton, the method may further comprise diagnosing whether the subject has cancer. When the subject has been treated for cancer and imaging the subject's skeleton is performed, the method may further comprise evaluating or monitoring the efficacy of the treatment.

[0029] Also provided is a method of binding a conjugate or a pharmaceutically acceptable salt thereof to hydroxyapatite in a subject. This method may comprise administering to the subject an effective amount of: (i) a conjugate or a pharmaceutically acceptable salt thereof; or (ii) a pharmaceutical composition (e.g., comprising the conjugate or a pharmaceutically acceptable salt thereof). In some embodiments, the subject suffers from cancer (e.g., bone cancer). In some embodiments, the subject suffers from osteoblastic bone cancer. In some embodiments, the subject suffers from osteolytic bone cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] The embodiments disclosed herein and other features, advantages and aspects and matters for achieving them will become apparent from the following detailed description of various exemplary embodiments of the present disclosure, which will be better understood when combined with the accompanying drawings.

[0031] Figure 1 Luciferin bioluminescence is shown in the right femur of mice two weeks after initial tumor challenge, confirming tumor growth in the bone (bioluminescence is indicated by a circle).

[0032] Figure 2 Shown are micro-computed tomography (micro-CT) images of the right tibia of mice two weeks after initial tumor challenge, demonstrating severe bone resorption due to tumor growth.

[0033] Figure 3 Shows the Figure 1 Fluorescence of DD10-S0456 tumor-induced bone lesions in mice shown (fluorescence is indicated by circles).

[0034] Figure 4 The reaction scheme of the fluorescent imaging conjugate DD10-S0456 is shown. In each identified step, the addition / scheme is as follows: (1) 1 equivalent of S0456 and 5 equivalents of CsCO3 in dimethyl sulfoxide (DMSO) were added at room temperature (RT) and reacted for 4 hours; (2) a) Boc deprotection, 40% trifluoroacetic acid (TFA) in dichloromethane (DCM) was added at room temperature for 40 minutes; and b) 1 equivalent of 3-maleimidopropionic acid, 1 equivalent of benzotriazol-1-yloxytripyrrolidinophosphine hexafluorophosphate (PyBOP) and 5 equivalents of N,N-diisopropylethylamine (DIPEA) in anhydrous DMSO were added at room temperature for 4 hours. And (3) 1 equivalent of DD10-Cys-Fmoc in anhydrous DMSO was added at room temperature and reacted for 4 hours.

[0035] Figure 5 Reaction schemes for the radioimaging and radiotherapeutic conjugates K(DOTA)-VMF-DD10 and K(DOTA)-F-DD10 are shown. While DOTA is the chelator shown in the scheme, it is understood that other chelators with similar functional groups can also be attached in a similar manner.

[0036] Figure 6 Lys(DOTA)-Phe-D-Asp is shown 10 (also known as K(DOTA)-F-DD10 or KDFDD10) structure.

[0037] Figure 7 Lys(DOTA)-Val-Met-Phe-D-Asp is shown 10 (also known as K(DOTA)-VMF-DD10 or KDVMFDD10) structure.

[0038] Figure 8 Shows the injection 111Single photon emission computed tomography / computed tomography (SEPCT / CT) images of mice bearing tibial tumors with In-chelated K(DOTA)-F-DD10 (220 μCi injected at a dose of 200 μCi / 10 nmol). Arrows indicate the site of tumor growth and white boxes indicate kidneys. From left to right: images were taken at 1 hour, 4 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, and 120 hours after injection of the radioactive imaging agent.

[0039] Fig. 9 Shows the injection 111 Single photon emission computed tomography (SPECT) / computed tomography (CT) images of mice bearing tibial tumors with In-chelated K(DOTA)-VMF-DD10 (375 μCi injected at a dose of 300 μCi / 10 nmol). Arrows indicate the site of tumor growth and white boxes indicate kidneys. From left to right: images were taken at 1 hour, 4 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, and 120 hours after injection of the radioactive imaging agent.

[0040] Fig.10 SPECT / CT images of healthy mice are shown, with the top row of mice injected with 111 In chelated K(DOTA)-F-DD10 (160 μCi at a dose of 200 μCi / 10 nmol), bottom row mice were injected 111 In-chelated K(DOTA)-VMF-DD10 (350 μCi injected at a dose of 300 μCi / 10 nmol). Arrows indicate kidneys. From left to right: images were taken at 1 hour, 4 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, and 120 hours after injection of the radiocontrast agent.

[0041] Fig.11 Shows the injection 177 SPECT / CT images of mice bearing tibial tumors with Lu-chelated K(DOTA)-F-DD10 (0.962 mCi at a dose of 1.5 mCi / 10 nmol). Arrows indicate the site of tumor growth and white boxes indicate kidneys. From left to right: images at 3, 24, 48, 72, 96, 120, and 168 hours after injection of the radiotherapeutic agent.

[0042] Fig.12 Shows the injection 177SPECT / CT images of mice bearing tibial tumors injected with Lu-chelated K(DOTA)-F-DD10 (3.0 mCi / 10 nmol dose of 3.0 mCi). Arrows indicate the site of tumor growth and white boxes indicate kidneys. From left to right: images at 3, 24, 48, 72, 96, 120, and 168 hours after injection of the radiotherapeutic agent.

[0043] Fig.13 Shows the injection 177 SPECT / CT images of mice bearing tibial tumors with Lu-chelated K(DOTA)-F-DD10 (3.57 mCi at a dose of 3.0 mCi / 10 nmol). Arrows indicate the site of tumor growth and white boxes indicate kidneys. Top row from left to right: images at 2 hours, 12 hours, 24 hours, and 48 hours after injection of the radiotherapeutic agent. Bottom row from left to right: images at 72 hours, 96 hours, 144 hours, and 196 hours after injection of the radiotherapeutic agent.

[0044] Fig.14 Shows the injection 177 SPECT / CT images of mice bearing tibial tumors with Lu-chelated K(DOTA)-F-DD10 (5.50 mCi injected at a dose of 6.0 mCi / 10 nmol). Arrows indicate the site of tumor growth and white boxes indicate kidneys. Top row from left to right: images at 2 hours, 12 hours, 24 hours, 48 ​​hours, and 72 hours after injection of the radiotherapeutic agent. Bottom row from left to right: images at 96 hours, 144 hours, 196 hours, and 240 hours after injection of the radiotherapeutic agent.

[0045] Fig.15 Shown is a reaction scheme for the construction of the radioimaging and radiotherapeutic conjugate K(DD10F2)VM-DOTA from the carboxyl terminus to the amino terminus. Steps 1-4 identified under the third arrow include: 1) Alloc deprotection; 2) KVM-DOTA + DD10F2-Fmoc coupling; 3) Fmoc deprotection; 4) deprotection and cleavage.

[0046] Fig.16 Lys(D-Asp 10 -Phe2)-Val-Met-DOTA (also known as K(DD10F2)VM-DOTA).

[0047] Fig.17 Shows 177 The structure of Lu-complexed DOTA conjugate, where the base conjugate contains Figure 6 The conjugate.

[0048] Fig.18 Shows 111In the structure of the complex DOTA conjugate, where the base conjugate contains Figure 6 The conjugate.

[0049] While the disclosure is susceptible to various modifications and alternative forms, exemplary embodiments thereof have been shown by way of example in the drawings and are herein described in detail. DETAILED DESCRIPTION

[0050] The present disclosure is based, at least in part, on the use of polyanionic polymers, polyacidic polymers and / or polyelectrolyte polymers (e.g., polymers comprising or consisting of acidic amino acids (e.g., L and / or D, aspartic acid and / or glutamic acid)) to target hydroxyapatite (e.g., the positively charged calcium head of hydroxyapatite). The present invention provides a conjugate comprising a group of polyanionic ligands, polyacidic ligands and / or polyelectrolyte ligands (e.g., the carboxyl terminus, amino terminus and / or carboxyl side chains of acidic peptides) that bind to hydroxyapatite, coupled to an active agent, such as an imaging agent, a radiotherapeutic agent, a radiosensitizer and / or a radioprotectant. In certain embodiments, the polyanionic ligands, polyacidic ligands and / or polyelectrolyte ligands can be attached to the active agent via a linker (optionally also including a spacer). Such conjugates can be used to target the delivery of the above-mentioned active agents to damaged or diseased bones, such as bones containing cancer-induced lesions, for diagnostic and / or therapeutic (e.g., "theranostic") purposes.

[0051] When cancer cells invade bones, they secrete various compounds (such as cytokines or growth factors) to induce excessive proliferation and activation of osteoclasts (i.e., bone degeneration cells). The osteoclasts can then degenerate bones and promote tumor growth by releasing various growth factors and compounds previously locked in the bone matrix. During bone resorption, hydroxyapatite can be exposed to blood vessels and become a target. Although hydroxyapatite may be exposed in normal healthy bones because bones are constantly metabolized to maintain bone homeostasis (the balance between formation and degradation), this exposure is negligible compared to exposure in diseased or damaged bones. In addition, unlike other receptors, the exposed hydroxyapatite content is high and therefore will not be easily saturated by clinical therapeutic doses. These characteristics make hydroxyapatite a potential receptor for selective delivery of active agents.

[0052] Conjugate

[0053] The conjugate can be combined with hydroxyapatite. The conjugate can deliver imaging agents, radiotherapeutic agents, radiosensitizers and / or radioprotective agents to damaged or diseased bones, such as bones containing cancer-induced lesions, for therapeutic diagnosis purposes.

[0054] In certain embodiments, the conjugate comprises Formula I: HB-L A -A(Formula I) or a pharmaceutically acceptable salt thereof, wherein HB is a group of anionic ligands, acidic ligands and / or electrolyte ligands (e.g., binding to hydroxyapatite); A is an active agent, including a radioactive imaging agent, a radiosensitizer, a radioprotectant or a radiotherapeutic agent; and, optionally, L A is a linker that binds HB and A, or is absent.

[0055] In certain embodiments, L A is optional. If L is not included A , HB is directly conjugated to A. For example, in certain embodiments, the conjugate comprises formula IA: HB-A (Formula IA) or a pharmaceutically acceptable salt thereof, wherein HB is a group of anionic ligands, acidic ligands and / or electrolyte ligands (eg, binding to hydroxyapatite); and A is an active agent, including a radioimaging agent, a radiosensitizer, a radioprotectant or a radiotherapeutic agent.

[0056] In certain embodiments, the anionic ligand, acidic ligand and / or electrolyte ligand are straight chain (for example, non-branched) anionic ligand, acidic ligand, and / or electrolyte ligand. In certain embodiments, the anionic ligand, acidic ligand and / or electrolyte ligand are branched anionic ligand, acidic ligand, and / or electrolyte ligand. The part (for example HB) can be a biological targeting part with one or more negative charges or can otherwise interact with positively charged calcium hydroxyapatite. In certain embodiments, the part comprises peptide or peptide analog (can be linear peptide, cyclic peptide, branched peptide or their combination) and / or one or more polymers. The part can be synthetic or natural.

[0057] The part (e.g., HB) can include 1 to about 50 (e.g., 1-50) anionic moieties, acidic moieties, and / or electrolyte moieties. In certain embodiments, the part comprises a polyacid ligand. The polyacid ligand comprises a repeating unit with an acidic moiety. Examples of acidic moieties include, but are not limited to, carboxylic acid moieties, sulfonic acid moieties, boric acid moieties, and phosphonic acid moieties. The acidic moiety can be an acidic macromolecule, such as nucleic acid, actin, or proteoglycan. In certain embodiments, the part (e.g., HB) comprises a polyacid peptide and / or a polymer, such as a polyglutamic acid peptide, etc.

[0058] In certain embodiments, the ligand comprises a polyelectrolyte ligand. The polyelectrolyte ligand may comprise a repeating unit with an electrolyte moiety. Examples of electrolyte moieties include, but are not limited to, sulfonates, acrylates, and phosphates.

[0059] In certain embodiments, the part comprises 1 to about 50 (e.g., 1-50) anionic moieties. In certain embodiments, the part comprises a polyanion. A polyanion is a polyelectrolyte subgroup consisting of repeating anionic moieties (e.g., polymer-based moieties). Examples of anionic moieties include, but are not limited to, phosphates and polyphosphates.

[0060] The ligand (e.g., HB) may comprise an amino acid or a derivative thereof. As used herein, "amino acid" refers to an L- or D-amino acid, an amino acid analog, or an amino acid mimetic, which may be naturally occurring or purely synthetic, and may be an optional pure product (i.e., a single enantiomer, therefore chiral, or a mixture of enantiomers). As used herein, "amino acid mimetic" refers to a synthetic analog of a naturally occurring amino acid, which is an isostere (i.e., designed to simulate the spatial structure and electronic structure of a natural compound). The amino acid may be natural or non-natural, essential or non-essential. The amino acid may have any suitable relative configuration (e.g., D- or L- configuration as described above). The HB may comprise L-aspartic acid, D-aspartic acid, L-glutamic acid, D-glutamic acid, or a derivative thereof, or a mixture of two or more of the above amino acids or their derivatives.

[0061] The ligand (e.g., HB) may also include one or more hydrophobic moieties coupled to the groups of anionic ligands, acidic ligands, and / or electrolyte ligands, such as 1 to about 30 (e.g., 1-30) hydrophobic moieties (e.g., alkyl or alkenyl), ultraviolet (UV) active moieties (e.g., phenylalanine (Phe), tyrosine (Tyr), and / or tryptophan (Trp)), or active group protecting moieties (e.g., 9-fluorenylmethoxycarbonyl (Fmoc), allyloxycarbonyl (Alloc), and / or tert-butyl). "Alkyl" generally refers to a straight or branched hydrocarbon chain group consisting only of carbon and hydrogen atoms, such as a group having 1 to 15 carbon atoms (e.g., C1-C 15 Unless otherwise indicated, "alkyl" disclosed herein is intended to include independent descriptions of saturated "alkyl". Alkyl groups may contain 1 to 13 carbon atoms (e.g., C1-C 13 Alkyl groups may contain 1 to 8 carbon atoms (e.g., C1-C8 alkyl groups). Alkyl groups may contain 1 to 5 carbon atoms (e.g., C1-C5 alkyl groups). Alkyl groups may contain 1 to 4 carbon atoms (e.g., C1-C4 alkyl groups). Alkyl groups may contain 1 to 3 carbon atoms (e.g., C1-C3 alkyl groups). Alkyl groups may contain 1 to 2 carbon atoms (e.g., C1-C2 alkyl groups). Alkyl groups may contain 1 carbon atom (e.g., C1 alkyl groups). Alkyl groups may contain 5 to 15 carbon atoms (e.g., C5-C 15The alkyl group may be selected from methyl, ethyl, 1-propyl (n-propyl), 1-methylethyl (isopropyl), 1-butyl (n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (isobutyl), 1,1 dimethylethyl (tert-butyl) and 1-pentyl (n-pentyl). The alkyl group is attached to the rest of the molecule by a single bond.

[0062] The ligand (eg, HB) may also comprise (i) a serum albumin binder (AB) directly conjugated to HB, or (ii) AB and a linker L. AB (AB-L AB ), where AB-L AB By L AB Conjugated to HB. In certain embodiments, AB is attached to the amino or carboxyl terminus of the poly(acid) peptide, or to an active or functional group (e.g., by way of non-limiting example, a carboxyl, amine or thiol group) of the anionic, acidic or electrolyte portion of the HB repeat. AB can be attached directly to HB, or can be attached to HB via a linker L. AB In certain embodiments, AB is attached by using a maleimide linker (e.g., see Figure 4 A maleimide-thiol linker in, in this case, to conjugate the dye to the targeting moiety), a disulfide linker, or any other linker that can react with a sulfur group is attached to the thiol group of the HB. In some embodiments, the HB does not contain an AB.

[0063] Examples of AB include, but are not limited to, Evans blue, Fmoc, diphenylcyclohexanol phosphate, naphthoylsulfonamide, 4-(p-X-phenyl)butanoic acid (wherein X is -H, -C1-C6 alkyl, -F, -Cl, -Br, -I, -OC 1-6 alkyl, -CN, -CHO, -B(OH)2, -C=CC(O)aryl, -C=CS(O)2aryl, -CO2H, -SO3H, -SO2NH2, -PO3H2, -SO2F, CF3), or derivatives of any of the above. Other examples of AB include, but are not limited to:

[0064] AB may contain a hapten. Examples of haptens include, but are not limited to, 2,4-dinitrophenol (DNP), 2,4,6-trinitrophenol (TNP), rhamnose, galactose-α-1,3-galactose (α-Gal), or an antibody binder. Examples of antibody binders include, but are not limited to, Fab, scFv, VH 、V L 、V H H, V-NAR, monobody, anticalin, affibody and DARPin.

[0065] HB may comprise a linear polyanionic group of formula X-A1, X-A2, X-A3 or X-A4: in: R is COOH for L- or D-aspartic acid, CH2COOH for L- or D-glutamic acid, or CH2CH2COOH for an unnatural acidic amino acid; n = 1-50; and Indicates AB or L AB attachment point.

[0066] In some embodiments, HB does not contain an albumin binder as shown in formula X-A3 and X-A4. HB may contain a branched polyanionic group of formula X-A5, X-A6, X-A7 or X-A8: in: R is COO- for L- or D-aspartic acid, CH2COO- for L- or D-glutamic acid, or CH2CH2COO- for an unnatural acidic amino acid; n = 1-50; Indicates that L A attachment point; and, When HB also contains AB or AB-L AB hour, Indicates AB or L AB attachment point, and represents the point of attachment to hydrogen or HB. In certain embodiments, HB does not comprise any albumin binder as shown in Formulae X-A7 and X-A8.

[0067] By L A and L ABThe linker represented by can be any suitable linker. The linker can contain atoms selected from C, N, O, S, Si and P; C, N, O, S and P; or C, N, O and S. The linker can have a backbone of varying lengths, such that there can be as few as two atoms in the linker backbone and up to 100 or more continuous atoms in the linker backbone. The linker "backbone" is the shortest continuous chain of atoms that forms a covalent bond between HB and A. In some embodiments, the multivalent linker has a branched backbone, each branch acting as a segment of the backbone linker until the end is reached.

[0068] For example, the linker chain length is at least about 7 atoms. In some embodiments, the linker length is at least about 10 atoms. In some embodiments, the linker length is at least about 14 atoms. In some embodiments, the linker is between about 7 to about 31 atoms (e.g., about 7 to 31, 7 to about 31, or 7 to 31), between about 7 to about 24 atoms (e.g., about 7 to 24, 7 to about 24, or 7 to 24), or between about 7 to about 20 atoms (e.g., about 7 to 20, 7 to about 20, or 7 to 20). In some embodiments, the linker is between about 14 to about 31 atoms (e.g., about 14 to 31, 14 to about 31, or 14 to 31), between about 14 and about 24 atoms (e.g., about 14 to 24, 14 to about 24, or 14 to 24), or between about 14 and about 20 atoms (e.g., about 14 to 20, 14 to about 20, or 14 to 20). In some embodiments, the linker chain length is at least 7 atoms, at least 14 atoms, at least 20 atoms, at least 25 atoms, at least 30 atoms, or at least 40 atoms; or 1 to 15 atoms, 1 to 5 atoms, 5 to 10 atoms, 5 to 20 atoms, 10 to 40 atoms, or 25 to 100 atoms.

[0069] L A and L AB It may contain at least one carbon-carbon bond and / or at least one amide bond. A and L AB One or more L- or D- configurations, natural or non-natural amino acids, polyethylene glycol (PEG) monomers, PEG oligomers, PEG polymers or any combination of the foregoing may be included. For linkers comprising one or more PEG units, unless otherwise specified, all carbon and oxygen atoms of the PEG units are part of the backbone.

[0070] L A and L AB The oligomer may comprise peptidoglycan, polysaccharide, anion or a combination of any of the above. A and L ABIt may contain at least one 2,3-diaminopropionic acid group, at least one glutamic acid group, at least one cysteine ​​group, or a combination of two or more thereof.

[0071] In certain embodiments, L A and / or L AB In certain embodiments, L A and / or L AB An amino acid linker (eg, a lysine (Lys) linker as described in Example 4 below) is included.

[0072] L A and / or L AB Can each independently be a quick-release joint. A and / or L AB It can be a slow-release joint independently. As used herein, in the context of a joint, the term "fast release" refers to a joint, including at least one releasable bond known in the art and / or a bond that can be cleaved to varying degrees under certain conditions, particularly when in or otherwise exposed to certain metabolic, physiological or cellular conditions, a bond that can be broken or cleaved in less than about 1 week, these conditions may trigger a series of ruptures or bond cleavages (e.g., this may result in the release of one or more parts connected by one or more parts of the joint (e.g., HB and A)). Key cleavage can be carried out by a standard chemical hydrolysis reaction, the reaction is, for example, carried out at a physiological pH value, or due to compartmentalization into an organelle (e.g., an endosome with a pH lower than the cytosolic pH). Key cleavage can also be carried out by an acid-catalyzed elimination reaction. Or, for example, cleavage can be initiated by a nucleophilic attack on the disulfide group of the fast-release joint, causing cleavage to form a thiol ester. In any of these cases, the fast-release properties of this joint can be achieved by any mechanism associated with the chemical, metabolic, physiological or biological conditions present. In certain embodiments, the immediate release linker comprises one or more sulfide bridges.

[0073] In contrast, in the context of a linker, "slow release" refers to a linker that comprises at least one bond that is not easily or quickly broken (i.e., the bond will not cleave), and although it may cleave or break to varying degrees under certain conditions, it will not cleave, break or otherwise release one or more of the parts connected by one or more parts of the linker (e.g., HB and A) when subjected to certain metabolic, physiological or cellular conditions, which may trigger a series of breaks (e.g., after administration to a subject) that lasts for more than about 1 week (e.g., 1 week), more than about 1 month (e.g., 1 month), more than about 4 months (e.g., 4 months), more than about 6 months (e.g., 6 months), or more than about 1 year (e.g., 1 year). In certain embodiments, the slow release linker comprises one or more amide bonds.

[0074] The conjugates of the present invention can be formulated with an immediate release linker or a sustained release linker as needed and / or suitable for a particular application. Generally, for imaging and radiotherapy applications, it is generally desirable that the active agent and / or imaging agent is not readily released to the subject after administration. Therefore, conjugates for imaging or radiotherapy applications may be more likely to include a sustained release linker than an immediate release linker.

[0075] On the other hand, the common feature of peptide-based drugs is high and / or continuous uptake by the kidney, which may reduce the sensitivity of detection of lesions near the kidney and renal toxicity, because the kidney is the main organ responsible for excreting these drugs from the body. There are many ways to reduce renal uptake and retention, such as administering positively charged amino acids (such as lysine) together with the drug. Another conventional method is to utilize unnatural amino acids (UAA), such as D-amino acids, because these amino acids are not easily recognized by renal proteins compared to natural amino acids. In addition or alternatively, a quick-release linker can be incorporated into a conjugate that can be broken or cracked in the kidney to prevent uptake.

[0076] The brush border is the name of the microvilli-covered surface of pseudostratified columnar epithelium found in multiple locations in the body, two major locations being the small intestine and the kidney. In the kidney, the brush border can be used to distinguish the proximal tubules (which have a brush border) from the distal tubules (which do not have a brush border). In the proximal tubules of the kidney, various brush border membrane (BBM) peptidases can bind to peptides and cleave them so that the peptides can be recovered or excreted. Several BBM peptidases are known in the art (all are immediate release linkers), including the tripeptide Met-Val-Lys, the dipeptide Gly-Lys, and the tripeptide Gly-Phe-Lys. The term "peptidase" refers to an enzyme that hydrolyzes peptide bonds between amino acids. Previous studies have tested these sequences as linkers between targeting moieties and bioactive agents and demonstrated that including these linkers in conjugates can accelerate renal clearance.

[0077] In certain embodiments, L AA BBM peptidase linker is included. The BBM linker may be an immediate release linker. Insertion of a BBM linker between the ligand / targeting moiety (HB) and the imaging or therapeutic agent (A) of the conjugate allows recognition and cleavage by renal brush border enzymes.

[0078] In certain embodiments, the BBM linker comprises a cleavable tripeptide Met-Val-Lys. When a conjugate comprising a BBM linker is administered to a subject (e.g., systemically), the BBM linker can be cleaved and release the ligand / targeting moiety (HB) and the imaging or therapeutic agent (A) therefrom (e.g., under physiological conditions).

[0079] In certain embodiments, the BBM linker may include one or more UAA, including but not limited to one or more of D-amino acids, citrulline, hydroxyproline, norleucine, 3-nitrotyrosine, nitroarginine, naphthylalanine, aminobutyric acid (Abu), 2,4-diaminobutyric acid (DAB), methionine sulfoxide, methionine sulfone, and the like.

[0080] It should be understood that physiological conditions that cause the cleavage of the BBM linker include standard chemical hydrolysis reactions, such as those carried out at physiological pH, or due to compartmentalization into organelles (e.g., endosomes having a pH lower than the cytosolic pH). Exemplarily, the BBM linkers described herein can be cleaved (e.g., released immediately) under certain metabolic, physiological, or cellular conditions that may trigger a series of cleavages or bond cleavages (e.g., which may release one or more moieties (e.g., HB and A) connected by one or more moieties of the linker).

[0081] To form L A and L AB The atoms of L can be combined in all chemically relevant ways, for example, a chain of carbon atoms to form an alkylene group, a chain of carbon and oxygen atoms to form a polyoxyalkylene group, a chain of carbon and nitrogen atoms to form a polyamine, etc. Furthermore, the bonds connecting the atoms in the chain can be saturated or unsaturated, so that, for example, alkanes, alkenes, alkynes, cycloalkanes, arylenes, imides, etc. can be L. A and L AB In addition, the atoms forming the linker may be cyclized with each other to form a saturated or unsaturated divalent cyclic group in the linker.

[0082] In some embodiments, L A and L AB Can contain a portion that is neutral under physiological conditions. In some embodiments, L A and L ABL may contain moieties that can be protonated or deprotonated to carry one or more positive charges or one or more negative charges, respectively. A and L AB Neutral moieties and moieties that can be protonated to carry one or more positive charges can be included.

[0083] Examples of neutral moieties include polyhydroxyl groups (eg, sugars, carbohydrates, saccharides, inositols, etc.), and / or polyether groups (eg, polyoxyalkylene groups, including polyoxyethylene, polyoxypropylene, etc.).

[0084] Examples of moieties that can be protonated to carry one or more positive charges include amino groups, such as polyaminoalkylenes (including ethylenediamine, propylenediamine, butylenediamine, etc.), and / or heterocycles (including pyrrolidine, piperidine, piperazine) and other amino groups, each of which can be optionally substituted. In certain embodiments, L A and L AB It may contain a positively charged moiety comprising one or more lysine residues.

[0085] Examples of moieties that can be deprotonated to carry one or more negative charges include carboxylic acids (eg, aspartic acid, glutamic acid, and long chain carboxylic acid groups), and sulfates (eg, alkyl sulfates).

[0086] Alternatively, or in addition to chain length, in some embodiments, L A and L AB has suitable substituents that can influence the hydrophobicity or hydrophilicity. Thus, for example, L A and L AB It may have hydrophobic side chain groups, such as alkyl, cycloalkyl, aryl, aralkyl and the like, each of which may be optionally substituted. A and L AB includes one or more amino acids, then L A and L AB It may contain hydrophobic amino acid side chains, such as one or more amino acid side chains of Phe and Tyr (including substituted variants thereof), as well as analogs and derivatives of such side chains.

[0087] L A and L ABAny one or both of can comprise a sustained-release joint. In some embodiments, the sustained-release joint comprises a framework that is stable under physiological conditions (e.g., the framework is not easily hydrolyzed (e.g., aqueous phase hydrolysis or enzymatic hydrolysis)). In some embodiments, the sustained-release joint does not release any component conjugated thereto. In some embodiments, the sustained-release joint lacks a disulfide bond (e.g., SS) or ester in the framework. In some embodiments, HB and A are connected by a framework that is substantially stable throughout the entire period of the composition circulation (e.g., in vivo circulation). The sustained-release joint may comprise an alkyl (alkenyl), anhydride, amide, ester, ether, amine and / or thioether (e.g., thiomaleimide). Any sustained-release joint can be used, as long as at least one bond that is not easily or quickly broken under physiological conditions is formed.

[0088] In some embodiments, the non-releasable linker comprises a linker that will hydrolyze at neutral pH, e.g., less than ten percent (10%) (e.g., less than 5%, less than 4%, less than 3%, less than 2%, less than 1%, less than 0.1%, less than 0.01%, or less than 0.001%) in an aqueous solution, e.g., a buffer solution (e.g., a phosphate buffer solution) over a period of time (e.g., 24 hours). In some embodiments, when a slow-release linker is used, less than about ten percent (10%), preferably less than five percent (5%), or none of the administered conjugate releases A (e.g., in the systemic circulation and then taken up by target cells / tissues). In some embodiments, within one (1) hour of administration, when the compound is in the systemic circulation, less than five percent (5%) of A is released from the conjugate.

[0089] L A A quick-release linker may be included. For example, when subjected to physiological conditions (e.g., in serum circulation), the quick-release linker can release A relatively quickly from the conjugate. Examples of quick-release linkers include, but are not limited to, esters, disulfides, and sulfhydryls. L A An immediate release linker may be included. The cleavable bond of the immediate release linker may be part of the backbone.

[0090] The connector L ACan comprise biodegradable, pH sensitive, self-degrading, peptidase sensitive or hydrolyzable joint. Examples of these joints include, but are not limited to, β-glucuronide joints, maleimide-based sulfhydryl joints, cathepsin K sensitive joints, cathepsin B sensitive joints, matrix metalloproteinase sensitive joints and BBM cleavable joints. Quick-release groups also include photochemical cleavable groups. Examples of photochemical cleavable groups include 2-(2-nitrophenyl)-ethane-2-ol groups and joints containing o-nitrobenzyl, diphenylacetophenone, trans-o-cinnamoyl, m-nitrophenyl or benzylsulfonyl groups (e.g., see Dorman and Prestwich, Trends Biotech.18:64-77 (2000); Greene & Wuts, Protective Groups in Organic Synthesis, 2nd ed., John Wiley & Sons, New York (1991)). The joint L A and L AB The conjugation may be to the N- or C-terminus of HB, any monomer of its polymer, or any substituent of any monomer of its polymer.

[0091] According to methods known in the art or methods developed below, immediate and sustained release linkers can be designed, for example, by pegylation, etc., to optimize biodistribution, bioavailability, and PK / PD (e.g., biodistribution, bioavailability, and PK / PD of A) and / or to increase target tissue uptake of A. In some embodiments, the linker is configured to avoid significant release of a pharmaceutically active amount of A into the circulation prior to being captured by cells.

[0092] It is understood that the instability of the immediate release bond can be adjusted by including functional groups or fragments in the linker that can assist or promote such bond cleavage (also known as ortho-promotion). The instability of the immediate release bond can also be adjusted by, for example, substitution changes at or near the immediate release bond, such as alpha branching adjacent to the immediate release disulfide bond, enhancing the hydrophobicity of the substituents on silicon in the portion with a hydrolyzable silicon oxygen bond, homologating the alkoxy group that forms part of a hydrolyzable ketal or acetal, etc. In addition, it is understood that additional functional groups or fragments can be included in the linker, which, when present, can assist or promote additional cleavage of the compound after the bond of the immediate release linker is broken.

[0093] L A Can contain L1 or L2: in Indicates L A Between A and LA and the attachment point between HB.

[0094] L A and L AB Either or both of L may comprise a spacer (e.g., be conjugated to and / or include a spacer). The spacer may be any suitable spacer. A and L AB The spacer may include a hydrophilic monomer, a hydrophobic monomer, an amphiphilic monomer, a non-peptide monomer, a peptide monomer and / or an aromatic monomer. The length of the spacer may range from 1 to 30 (e.g., 1 to 30 carbon atoms, PEG with 1-30 units, etc.). Examples of hydrophilic spacers include, but are not limited to, polyethylene glycol polymers and derivatives thereof. Examples of hydrophobic spacers include, but are not limited to, pure or mixed branched hydrocarbons, fluorocarbons, alkane polymers, olefin polymers and / or alkyne polymers. Examples of amphiphilic spacers include, but are not limited to, pure phospholipids or mixed phospholipids and / or derivatives thereof. Examples of peptide spacers include, but are not limited to, pure and mixed single, branched, L- or D- configurations, essential, non-essential, natural and non-natural amino acids and derivatives thereof. Examples of aromatic spacers include, but are not limited to, pure and mixed repeating quinones.

[0095] In some embodiments, the linker is formed by a click chemistry / click chemistry-derived synthesis method. Those skilled in the art will understand that the terms "click chemistry" and "click chemistry-derived" generally refer to a class of small molecule reactions commonly used for conjugation, thereby enabling the connection of a selected substrate to a specific molecule. Click chemistry is not a single specific reaction, but rather describes a method for generating products following examples from nature, which also generates substances by connecting small modular units. In many applications, click reactions connect biomolecules and reporter molecules. Click chemistry is not limited to biological conditions; the concept of "click" reactions has been used in pharmacological applications and various biomimetic applications. However, they have played a significant role in the detection, localization, and identification of biomolecules.

[0096] Click reactions can be performed in one pot, are generally undisturbed by water, produce minimal byproducts, and are "spring-loaded"—characterized by a large thermodynamic driving force that rapidly and irreversibly drives the reaction to a single reaction product in high yield, with high reaction specificity (and, in some cases, regio- and stereo-specificity). These properties make click reactions suitable for solving problems of isolating and targeting molecules in complex biological environments, where the products therefore need to be physiologically stable and any byproducts need to be nontoxic (e.g., to in vivo systems).

[0097] A can be an active agent, including a radioactive imaging agent, a radiosensitizer, a radioprotectant, or a radiotherapeutic agent. A can include a chelating agent (e.g., a chelating agent). In certain embodiments, the chelating agent (A) is directly or through a linker (L A ) is covalently attached to the ligand / biotargeting moiety (HB). The chelator may comprise a group suitable for direct or via a linker (L A ) is a functional group that is conjugated to the group of the ligand / biotargeting moiety (HB). The term "functional group suitable for conjugation" refers to a functional group that is conjugated to HB or L as needed. A A functional group that reacts with a corresponding functional group of the chelating agent (such as but not limited to an amine group, a carboxyl group or a thiol group) to chemically link the chelating agent thereto.

[0098] In certain embodiments, A comprises DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) or a derivative thereof (e.g., see Figure 6 , 7and 16). In certain embodiments, A comprises a chelating agent selected from the group consisting of: DOTA or a derivative thereof; TETA (1,4,8,11-tetraazacyclotetradecane-1,4,8,11-tetraacetic acid) or a derivative thereof; HEHA (1,2,7,10,13-hexaazacyclooctadecane-1,4,7,10,13,16-hexaacetic acid) or a derivative thereof; PEPA (1,4,7,10,13-pentaazacyclopentadecane-N,N',N",N"',N""-pentaacetic acid) or a derivative thereof; SarAr (1-N-(4-aminobenzyl)-3,6,10,13,16,19-hexaazabicyclo[6.6.6]-eicosane-1,8-diamine) or a derivative thereof; NOT A (1,4,7-triazacyclononane-1,4,7-triacetic acid) or its derivatives; NETA (4-[2-(dicarboxymethylamino)-ethyl]-7-carboxymethyl-[1,4,7]triazacyclononane-1-yl)acetic acid or its derivatives; TRAP (1,4,7-triazacyclononane-1,4,7-tri[methyl(2-carboxyethyl)phosphinic acid) or its derivatives; HBED (N,N0-bis(2-hydroxybenzyl)-ethylenediamine-N,N0-diacetic acid) or its derivatives; 2,3-HOPO (3-hydroxypyridin-2-one) or its derivatives; PCTA (3,6,9,15-tetraazabicyclo[9.3.1]-pentadeca-1(15),11,13-triene-3,6, 9-triacetic acid) or its derivatives; PDTA (1,3-propylenediaminetetraacetate) or its derivatives; NTA (nitrilotriacetate) or its derivatives; EDDS (ethylenediamine disuccinate) or its derivatives; EDTA (ethylenediaminetetraacetic acid) or its derivatives; MGDA (N-(1-carboxyethyl)iminodiacetate) or its derivatives; DFO (deferoxamine) or its derivatives; DTPA (diethylenetriaminepentaacetic acid) or its derivatives; CDTA ((1,2-cyclohexylidenenitrilo)tetraacetic acid) or its derivatives; CPTA (1,4,8,11-tetraazacyclotetradecane derivatives) or its derivatives; OCTAPA (N,N0-bis(6-carboxy-2-pyridylmethyl)-ethylenediamine-N ,N0-diacetic acid) or its derivatives; H2-MACROPA (N,N'-bis[(6-carboxy-2-pyridylmethyl]-4,13-diaza-18-crown-6) or its derivatives; H2dedpa (1,2-[[carboxy)-pyridin-2-yl]-methylamino]ethane or its derivatives; HEDP (hydroxyethylidene diphosphonate or etidronate) or its derivatives; HEBD (N,N'-bis(2-hydroxybenzyl)ethylenediamine-N,N'-diacetic acid) or its derivatives; HYNIC (6-hydrazinopyridine-3-carboxylic acid) or its derivatives; DMSA (meso-2,3-dimercaptosuccinic acid) or its derivatives; EC20 head comprising β-l-diaminopropionic acid, Asp and Cys.

[0099] The chelator may chelate a radioisotope. In certain embodiments, the radioisotope is a therapeutic radioisotope, such as an alpha emitting radioisotope (e.g. 225 Ac) or beta-emitting radioisotopes (e.g. 177 Lu or 90 Y). In certain embodiments, the conjugate comprises Fig.17 shown 177 Lu-complexed DOTA conjugate.

[0100] A of Formula I or Formula IA may comprise a chelating agent comprising an imaging radioisotope. In certain embodiments, the imaging radioisotope may be a gamma-emitting radioisotope, such as 111 In or 67 Ga. In certain embodiments, the conjugate comprises Fig.18 shown 111 In complex DOTA conjugate. The chelating agent can chelate 18 F. 44 Sc, 47 Sc, 52 Mn, 55 Co. 64 Cu, 67 Cu, 67 Ga, 68 Ga, 86 Y. 89 Zr, 90 Y. 99m Tc, 111 In, 114m In, 117m Sn, 124 I. 125 I. 131 I. 149 Tb, 153 Sm, 152 Tb, 155 Tb, 161 Tb, 177 Lu, 186 Re, 188 Re, 212 Pb, 212 Bi, 213 Bi, 223 Ra, 224 Ra, 225 Ab. 225 Ac or 227 In certain embodiments, the chelator is a positron emission tomography (PET) imaging radioisotope, such as 68 Ga,11 C. 13 N. 15 O and 18 F. A may include a selection from 14 C. 3 H. 34 S. 32 P. 125 I and 131 I. The radioactive reagent A can be connected by a linker L A Conjugation to the N- or C-terminus of HB, or to any reactive group on the HB repeating portion.

[0101] The above conjugates can be synthesized using methods known in the art and exemplified herein. For example, see Example 4.

[0102] The conjugate may have Figure 4 The conjugate may have Figure 6 The conjugate may have Figure 7 The conjugate may have Fig.16 The structure shown.

[0103] The conjugate may be present in the form of a pharmaceutically acceptable salt. Examples of acceptable salts include, but are not limited to, alkali metal (e.g., sodium, potassium or lithium) salts or alkaline earth metal (e.g., calcium) salts; however, any generally non-toxic and effective salt is acceptable when administered to the subject being treated. Similarly, "pharmaceutically acceptable salt" refers to a salt with a counter ion that can be used in a drug. Such salts may include, but are not limited to, (1) acid addition salts, which may be obtained by reacting the free base of the parent compound with an inorganic acid (e.g., hydrochloric acid, hydrobromic acid, nitric acid, phosphoric acid, sulfuric acid, perchloric acid, etc.), or with an organic acid (e.g., acetic acid, oxalic acid, (D) or (L) malic acid, maleic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, tartaric acid, citric acid, succinic acid, or malonic acid), etc.; or (2) salts formed when an acidic proton present in the parent compound is replaced by a metal ion (e.g., an alkali metal ion, an alkaline earth ion, or an aluminum ion), or coordinated with an organic base (e.g., ethanolamine, diethanolamine, triethanolamine, trimethamine, N-methylglucamine, etc.). Pharmaceutically acceptable salts are well known to those skilled in the art, and any such pharmaceutically acceptable salts may be considered.

[0104] Acceptable salts can be obtained using standard procedures known in the art including, but not limited to, reacting a sufficiently acidic compound with a suitable base to yield a physiologically acceptable anion. Suitable acid addition salts are formed from acids which form non-toxic salts. Illustrative but non-limiting examples include acetate, aspartate, benzoate, benzenesulfonate, bicarbonate / carbonate, bisulfate / sulfate, borate, camphorsulfonate, citrate, edisylate, ethanesulfonate, formate, fumarate, glucoheptonate, gluconate, glucuronate, hexafluorophosphate, hyaluronate, hydrochloride / chloride, hydrobromide / bromide, hydroiodide / iodide, isethionate, lactate, malate, maleate, malonate, methanesulfonate, methylsulfate, naphthylate, 2-naphthalenesulfonate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, phosphate / hydrogenphosphate / dihydrogenphosphate, sucrose, stearate, succinate, tartrate, toluenesulfonate and trifluoroacetate. Suitable base salts of the compounds can be formed from bases that form non-toxic salts. Illustrative but non-limiting examples include arginine salts, benzathine penicillin salts, calcium salts, choline salts, diethylamine salts, diethanolamine salts, glycine salts, lysine salts, magnesium salts, meglumine salts, ethanolamine salts, potassium salts, sodium salts, tromethamine salts, and zinc salts. Hemisalts of acids and bases can also be formed, such as hemisulphate and hemicalcium salts.

[0105] The conjugates herein may be "deuterated", meaning that one or more hydrogen atoms may be replaced by deuterium. Since deuterium and hydrogen have almost identical physical properties, deuterium substitution is the smallest structural change that can be made. Deuteration is well known to those of ordinary skill in the art.

[0106] In some embodiments, the conjugate may contain one or more asymmetric centers, thereby producing enantiomers, diastereomers and other stereoisomeric forms, which are defined as (R)- or (S)- in terms of absolute stereochemistry. In certain embodiments, the conjugate is in R- configuration. In certain embodiments, the conjugate is in S- configuration. Unless otherwise stated, all stereoisomeric forms of the conjugate are intended to be considered. When the conjugate contains an olefin double bond, unless otherwise stated, E and Z geometric isomers (e.g., cis or trans) are intended to be included. In certain embodiments, HB and A are arranged in a relative cis orientation. In certain embodiments, HB and A are arranged in a relative trans orientation. Similarly, all possible isomers, as well as their racemic and optically pure forms, and all tautomeric forms are also intended to be included. The term "geometric isomer" refers to an E or Z geometric isomer (e.g., cis or trans) of an olefin double bond. The term "positional isomers" refers to structural isomers around a central ring, for example, ortho-, meta-, and para-isomers around a benzene ring.

[0107] Pharmaceutical composition

[0108] In view of the above, a pharmaceutical composition comprising any of the conjugates is also provided. In certain embodiments, the pharmaceutical composition provided herein comprises a conjugate (e.g., a conjugate of formula (I) or formula (IA)) and one or more pharmaceutically acceptable carriers or excipients. The term "composition" generally refers to any product comprising more than one ingredient, including the conjugate. The composition can be prepared from an isolated conjugate or from salts, solutions, hydrates, solvates and other forms of the conjugate.

[0109] In certain embodiments, the conjugate of the composition comprises a conjugate of Formula I (or a pharmaceutically acceptable salt thereof): HB-L A -A(Formula I) wherein HB is a group of (e.g., linear or branched) anionic ligands, acidic ligands and / or electrolyte ligands (e.g., binding to hydroxyapatite); A is an active agent, including a radioimaging agent, a radiosensitizer, a radioprotectant or a radiotherapeutic agent; and L A is a linker that binds HB and A (as described herein). A is optional. If L is not included A , then HB is directly conjugated to A.

[0110] In certain embodiments, L A is optional. If L is not included A , then HB is directly conjugated to A. For example, in certain embodiments, the conjugate comprises formula IA: HB-A (Formula IA) or a pharmaceutically acceptable salt thereof, wherein HB is a group of anionic ligands, acidic ligands and / or electrolyte ligands (e.g., binding to hydroxyapatite); A is an active agent, including a radioactive imaging agent, a radiosensitizer, a radioprotectant or a radiotherapeutic agent. In certain embodiments, HB is used as a targeting portion of the conjugate.

[0111] In certain embodiments, the ligand (e.g., HB) may include 1 to about 50 (e.g., 1-50) anionic moieties, acidic moieties, and / or electrolyte moieties. In certain embodiments, the ligand (e.g., HB) may include an amino acid or a derivative thereof. In certain embodiments, the ligand (e.g., HB) may include an L-configuration. In certain embodiments, the ligand (e.g., HB) may include a D-configuration. In certain embodiments, the ligand (e.g., HB) may also include one or more hydrophobic moieties. The ligand (e.g., HB) may also include a ligand conjugated directly to HB or via a linker L AB(AB-L AB ) is conjugated with HB (e.g., wherein AB-L AB By L AB In some embodiments, the conjugate is in the R-configuration. In some embodiments, the conjugate is in the S-configuration.

[0112] In certain embodiments, the ligand (eg, HB) comprises a linear polyanionic group of formula X-A1, X-A2, X-A3, or X-A4: in: R is COOH for L- or D-aspartic acid, CH2COOH for L- or D-glutamic acid, or CH2CH2COOH for an unnatural acidic amino acid; n = 1-50; and Indicates AB or L AB attachment point.

[0113] HB may comprise a branched polyanionic group of formula X-A5, X-A6, X-A7 or X-A8: in: R is COO- for L- or D-aspartic acid, CH2COO- for L- or D-glutamic acid, or CH2CH2COO- for an unnatural acidic amino acid; n = 1-50; Indicates that L A attachment point; and, When HB also contains AB or AB-L AB hour, Indicates AB or L AB attachment point, and Indicates the point of attachment to hydrogen or HB.

[0114] In certain embodiments, the HB does not (may not) contain an albumin binder (e.g., Formula X-A3, X-A4, X-A7, and X-A8). A and L AB The linker represented can be any suitable linker (eg, a quick release linker or a slow release linker).

[0115] A can be an active agent, including a radioactive imaging agent, a radiosensitizer, a radioprotectant, or a radiotherapeutic agent. For example, A can include a chelator (e.g., any suitable chelator, including but not limited to the chelators specified herein in connection with the conjugate). A can include a radioisotope. A can include a PET imaging radioisotope. The active agent of A can be linked to a linker (e.g., L A ) is conjugated to the N- or C-terminus of HB or any reactive group on the HB repeating portion.

[0116] Certain functional groups, such as hydroxyl, amino, etc., can form complexes with water and / or various solvents in various physical forms of the conjugate.

[0117] The composition can be prepared from various amorphous, non-amorphous, partially crystalline, crystalline and / or other morphological forms of the conjugate, and the composition can be prepared from various hydrates and / or solvates of the conjugate. Therefore, such pharmaceutical compositions can include each of the various morphological forms and / or solvates or hydrate forms of the conjugate, or any combination or individual form thereof.

[0118] The pharmaceutical composition can include one or more pharmaceutically acceptable carriers, adjuvants, diluents, excipients and / or vehicles (e.g., conventional nontoxic pharmaceutically acceptable carriers, adjuvants and vehicles) and combinations thereof. Any pharmaceutically acceptable carrier and excipient known in the art can be used. Examples include, but are not limited to, excipients, colorants, preservatives and stabilizers. More specific examples include crystalline cellulose, carboxymethylcellulose calcium, carboxymethylcellulose sodium, hydroxypropyl cellulose, hydroxypropyl methylcellulose, ethyl cellulose and magnesium stearate.

[0119] Solutions of the active conjugate or pharmaceutical composition may be aqueous, optionally mixed with a non-toxic surfactant, and / or may contain carriers or excipients such as salts, carbohydrates and buffers (preferably at a pH of 3 to 9), but for certain applications they may be more suitably formulated as sterile non-aqueous solutions or dry forms for use in combination with a suitable vehicle (e.g., sterile pyrogen-free water or phosphate-buffered saline). For example, dispersions may be prepared in glycerol, liquid PEG, triacetin, mixtures thereof, and oils. Under normal conditions of storage and use, these preparations may also contain preservatives to prevent the growth of microorganisms.

[0120] The pharmaceutical composition may further comprise a radiosensitizer, a radioprotectant, an immunotherapeutic agent, a chemotherapeutic agent, an anticancer agent and / or a hormonal therapeutic agent. Alternatively, the conjugate (or a pharmaceutical composition comprising the conjugate) may be administered simultaneously or sequentially in any order with a radiosensitizer, a radioprotectant, an immunotherapeutic agent, an anticancer agent, a chemotherapeutic agent and / or a hormonal therapeutic agent (or a pharmaceutical composition comprising any of the foregoing).

[0121] The radiosensitizer may be any suitable radiosensitizer. Examples of suitable radiosensitizers include, but are not limited to, peptides or proteins, such as HER3-ADC, SYM004, cetuximab, nimotuzumab, AMG102, C-reactive peptide, HSP, paraoxonase-2, and ECI301; nanomaterials, such as gold (Au), GSH-modified Au, PEG-modified gold, silver (Ag), PEG-modified Ag, PVP-modified Ag, gadolinium (Gd), PEG-modified Gd, DTPA-modified Gd, hafnium (Hf), tantalum (Ta), tungsten (W), bismuth (Bi) and platinum (Pt); apaziquinone, curcumin, misonidazole, tirapazamine, AQ4N, paclitaxel, fluorouracil, cisplatin, dihydroartemisinin, resveratrol, etanidazole, porfibrinocin, TH-302, mitomycin C, nelfinavir, docetaxel, hydrogen peroxide, RRx-001, gemcitabine or papaverine hydrochloride. See, for example, Gong et al., Int J Nanomedicine 16: 1083-1102 (2021).

[0122] The radioprotectant can be any suitable radioprotectant. A non-limiting example of a suitable radioprotectant is amifostine. See, e.g., Gong et al. (2021), supra.

[0123] The immunotherapeutic agent can be any suitable immunotherapeutic drug. Examples of suitable immunotherapeutic drugs include, but are not limited to, transforming growth factor β (TGF-β) inhibitors (e.g., R268712), or programmed death-ligand 1 (PD-L1) inhibitors, such as Keytruda (pembrolizumab).

[0124] The anticancer agent can be any suitable anticancer drug. Examples of suitable anticancer drugs include, but are not limited to, kinase inhibitors, such as dasatinib. In some embodiments, A is not dasatinib, such as when HB comprises at least 4 amino acids (e.g., 4-20 amino acids).

[0125] The chemotherapeutic drug can be any suitable chemotherapeutic drug. Examples of suitable chemotherapeutic drugs include, but are not limited to, anthracyclines, such as doxorubicin, taxanes (such as docetaxel), cyclophosphamide (such as Cytoxan), or 5-fluoro-uracil.

[0126] The hormone therapy or hormone-related therapy can be any suitable hormone therapy or hormone-related therapy. Examples include, but are not limited to, hormone production inhibitors, such as Zoladex (goserelin) or letrozole.

[0127] The conjugate can be formulated into a pharmaceutical composition and administered to a mammalian host, such as a human patient, in a variety of forms suitable for the selected route of administration. The pharmaceutical composition can be formulated according to methods in the art, such as for a given route of administration, and manufactured, as described in, for example, Remington, The Science and Practice of Pharmacy, 22 nd The composition may be an infusion or injectable composition, for example a composition that can be injected subcutaneously or intravenously.

[0128] The pharmaceutical composition can be administered to a mammalian host, such as a human patient, in various forms suitable for the selected route of administration. In certain embodiments, the pharmaceutical composition is formulated for subcutaneous administration. In certain embodiments, the pharmaceutical composition is formulated for oral administration. In certain embodiments, the pharmaceutical composition is formulated for intramuscular, intravenous, intraarterial, intraperitoneal administration, or for administration by any other art-recognized parenteral administration route.

[0129] In certain embodiments, the pharmaceutical composition is combined with a pharmaceutically acceptable vehicle for systemic administration. The composition and formulation component percentages may vary and may be between about 1 to about 99% weight of the active ingredient (e.g., the conjugate) and binding agents, excipients, disintegrants, lubricants, and / or sweeteners (as known in the art). The amount of active conjugate in such therapeutically useful compositions is such that an effective dose level (e.g., in serum or target tissue) may be achieved.

[0130] Exemplary modes of parenteral administration include needle (including microneedle) syringes, needle-free syringes and infusion techniques, as well as any other parenteral administration methods recognized in the art. Parenteral formulations are typically aqueous solutions that may contain excipients such as salts, carbohydrates and buffers (preferably in the pH range of about 3 to about 9), but for some applications, they may be more suitable for formulation into sterile non-aqueous solutions or dry forms to be used in combination with a suitable vehicle (e.g., sterile pyrogen-free water). Preparation of parenteral formulations under sterile conditions, such as by lyophilization, can be easily achieved using standard pharmaceutical techniques well known to those skilled in the art.

[0131] The pharmaceutical dosage form that is applicable to use can comprise sterile aqueous solution or dispersion or sterile powder, comprise the active component that is applicable to instant preparation aseptic injectable or infusible solution or dispersion, and described composition is optionally encapsulated in liposome, nanocrystal or polymer nanoparticle.In all cases, final dosage form should be aseptic, mobile and stable under production and storage conditions.Liquid carrier or vehicle can be solvent or liquid dispersion medium, comprise for example but not limited to water, electrolyte, sugar, ethanol, polyol (for example glycerine, propylene glycol, liquid polyethylene glycol etc.), vegetable oil, nontoxic glyceride and / or its suitable mixture.In at least one embodiment, can by forming liposome, keep required particle diameter or use surfactant to keep required fluidity under the situation of dispersion.

[0132] Sterile injectable solutions can be prepared by combining the pharmaceutical composition with one or more of the above-mentioned other ingredients in the required amount in an appropriate solvent, followed by filtered sterilization. In the case of sterile powders for preparing sterile injectable solutions, vacuum drying and freeze drying techniques can be used, which can produce a powder of the active ingredient and any other desired ingredients present in the previously sterile-filtered solution.

[0133] method

[0134] A method for imaging and / or treating a subject's bones is also provided. The method comprises administering to the subject an effective amount of the following substances: (i) a conjugate of Formula I, Formula IA, or a pharmaceutically acceptable salt of Formula I or Formula IA, (ii) a first pharmaceutical composition comprising a conjugate of Formula I, a conjugate of Formula IA, or a pharmaceutically acceptable salt of Formula I or Formula IA, and optionally, wherein the first pharmaceutical composition further comprises a radiosensitizer, a radioprotectant, an immunotherapeutic agent, a chemotherapeutic agent, an anticancer drug or a hormone therapy agent, and a first pharmaceutically acceptable carrier or excipient. In addition, as required, the method may also comprise administering to the subject (i) or (ii) alone or further in combination with administering an active agent or a second pharmaceutical composition (comprising the active agent and a second pharmaceutically acceptable carrier or excipient). The active agent may be, for example, a radiosensitizer, a radioprotectant (e.g., Lys), an immunotherapeutic agent, a chemotherapeutic agent, an anticancer agent, or a hormone therapy agent.

[0135] As used herein, the term "administering" and variations thereof include all ways of introducing the compounds and compositions described herein into a subject, including, but not limited to, orally (po), intravenously (iv), intramuscularly (im), subcutaneously (sc), transdermally, by inhalation (e.g., intranasally (in)), buccally, intraocularly, sublingually, vaginally, rectally, and the like.

[0136] As used herein, "effective amount" refers to an amount sufficient to achieve the desired result or to have an effect on an undesirable condition. For example, an effective amount may refer to an amount sufficient to achieve the desired therapeutic result or to have an effect on a symptom. The specific effective dose level (e.g., amount) of any subject will depend on a variety of factors, including the condition being treated and the severity of the condition (e.g., the type, location, and severity of fractures, bone injuries, or cancer); the specific composition and / or conjugate used (i.e., its efficacy); the age, weight, general health, sex, and diet of the subject; the subject's response; the time of administration; the route of administration; the excretion rate of the specific conjugate used; the duration of treatment; the drug / active agent used in combination or simultaneously with the specific conjugate used, and similar factors well known in the medical field. For example, a person skilled in the art is fully capable of adding a dose of the conjugate / composition starting from a dose level lower than that required to achieve the desired therapeutic effect, and gradually increasing the dose until the desired effect is achieved. If necessary, the effective amount can be administered in multiple doses. Therefore, a single dose of the conjugate / composition may contain such an amount or a submultiple thereof to constitute a daily dose. The dosage may be adjusted by the individual physician if there are any contraindications. In addition, pharmacogenomic (the effect of genotype on the pharmacokinetic, pharmacodynamic, or pharmacodynamic characteristics of an antigen or composition) information about a particular patient will influence the dosage used to achieve an effective amount.

[0137] Depending on the route of administration, a wide range of permissible doses can be considered. For example, the effective amount of the conjugate and / or pharmaceutical composition can range from about 0.1 μg / kg / day, such as 0.5 μg / kg / day, 0.7 μg / kg / day, or 0.01 mg / kg / day up to about 1,000 mg / kg / day. Intravenous doses can be several orders of magnitude lower.

[0138] When the conjugate and / or the first pharmaceutical composition is administered with an active agent or a second pharmaceutical composition (comprising the active agent), the conjugate / first pharmaceutical composition and the active agent / second pharmaceutical combination can be administered to the subject simultaneously or sequentially in any order and using any mode of delivery. For example, but not limited to, the conjugate / first pharmaceutical composition can be administered intravenously (e.g., administered as an intravenous solution), and the active agent / second pharmaceutical composition can be administered subcutaneously. In other embodiments, both the conjugate / first pharmaceutical composition and the active agent / second pharmaceutical composition are administered intravenously. It is within the scope of the present disclosure to use a pharmaceutical composition comprising more than one drug / active agent.

[0139] The conjugate and any other active agent administered together (or sequentially) therewith can be administered at a therapeutically effective dose to obtain a clinically acceptable result, such as alleviation or elimination of symptoms or tumors. Therefore, the conjugate and any active agent can be administered simultaneously or sequentially in a treatment regimen. The administration of any active agent can be carried out according to treatment regimens known in the art.

[0140] Those skilled in the art will appreciate that treatment regimens may vary according to the needs of the subject. Thus, the conjugates and other compound (drug) combinations used in the methods of the present invention may be administered in accordance with variations of the regimens described herein. For example, during a treatment cycle, the conjugate and / or active agent may be administered discontinuously rather than continuously.

[0141] The conjugate of formula I (or a pharmaceutically acceptable salt thereof) can be any of the conjugates described herein. In certain embodiments, the conjugate or a pharmaceutically acceptable salt thereof has the following formula: HB-L A -A(Formula I) wherein HB is a group of (e.g., linear or branched) anionic ligands, acidic ligands and / or electrolyte ligands (e.g., binding to hydroxyapatite); A is an active agent, including a radioimaging agent, a radiosensitizer, a radioprotectant or a radiotherapeutic agent; and L A is a linker that binds HB and A, or is absent.

[0142] In certain embodiments, L A is optional. If L is not included A , then HB is directly conjugated to A. For example, in certain embodiments, the conjugate comprises formula IA: HB-A (Formula IA) or a pharmaceutically acceptable salt thereof, wherein HB is a group of anionic ligands, acidic ligands and / or electrolyte ligands (eg, binding to hydroxyapatite); and A is an active agent, including a radioimaging agent, a radiosensitizer, a radioprotectant or a radiotherapeutic agent.

[0143] In certain embodiments, the ligand (e.g., HB) comprises 1 to about 50 (e.g., 1-50) anionic moieties, acidic moieties, and / or electrolyte moieties. In certain embodiments, the ligand (e.g., HB) comprises an amino acid or a derivative thereof (e.g., an amino acid or a derivative thereof in an L- or D- configuration). In certain embodiments, the ligand (e.g., HB) further comprises one or more hydrophobic moieties. The ligand (e.g., HB) may also comprise a ligand conjugated directly to HB or via a linker L AB (AB-L AB ) is conjugated with HB (e.g., wherein AB-L AB By LAB Serum AB conjugated to HB).

[0144] In certain embodiments, the ligand (eg, HB) comprises a linear polyanionic group of formula X-A1, X-A2, X-A3, or X-A4: in: R is COOH for L- or D-aspartic acid, CH2COOH for L- or D-glutamic acid, or CH2CH2COOH for an unnatural acidic amino acid; n = 1-50; and Indicates AB or L AB attachment point.

[0145] HB may comprise a branched polyanionic group of formula X-A5, X-A6, X-A7 or X-A8: in: R is COO- for L- or D-aspartic acid, CH2COO- for L- or D-glutamic acid, or CH2CH2COO- for an unnatural acidic amino acid; n = 1-50; Indicates that L A attachment point; and, When HB also contains AB or AB-L AB hour, Indicates AB or L AB attachment point, and Indicates the point of attachment to hydrogen or HB.

[0146] In certain embodiments, the HB does not (may not) contain an albumin binder (e.g., Formula X-A3, X-A4, X-A7, and X-A8). A and L AB The linker represented can be any suitable linker (eg, a quick release linker or a slow release linker).

[0147] A of Formula I or Formula IA can be an active agent, including a radioactive imaging agent, a radiosensitizer, a radioprotectant, or a radiotherapeutic agent. For example, A comprises a chelator (e.g., any suitable chelator, including but not limited to the chelators specified herein in connection with the conjugate). A can comprise a radioisotope. A can comprise a PET imaging radioisotope. The active agent of A can be coupled to the conjugate by a linker (e.g., L A ) is conjugated to the N- or C-terminus of HB or any reactive group on the HB repeating portion.

[0148] In certain embodiments, the HB and A of the conjugate are arranged in a relative cis orientation. In certain embodiments, the HB and A of the conjugate are arranged in a relative trans orientation. In certain embodiments, the conjugate is in R-configuration. In certain embodiments, the conjugate is in S-configuration.

[0149] The method can also include administering an effective amount of an active agent or a pharmaceutical composition (e.g., a second pharmaceutical composition) comprising the active agent and a pharmaceutically acceptable carrier or excipient simultaneously or sequentially in any order, wherein the active agent is a free radiosensitizer, a radioprotectant, an immunotherapeutic agent, a chemotherapeutic agent, an anticancer drug, or a hormone therapy agent. In certain embodiments, the active agent comprises a radioprotectant. In certain embodiments, the radioprotective active agent comprises Lys.

[0150] The subject may have cancer, such as a primary bone cancer (e.g., osteosarcoma, chondrosarcoma, Ewing sarcoma, or chordoma), or a secondary bone cancer (e.g., metastatic breast cancer, prostate cancer, multiple myeloma, thyroid cancer, lung cancer, kidney cancer, ovarian cancer, colon cancer, or melanoma.

[0151] In certain embodiments, the method may further comprise imaging the subject's bone and / or the subject's cancer cell population (e.g., after administering the conjugate, a first pharmaceutical composition comprising the conjugate, or a first pharmaceutical composition comprising the conjugate and a radiosensitizer, a radioprotectant, an immunotherapeutic agent, a chemotherapeutic agent, an anticancer agent, and / or a hormonal therapeutic agent). Imaging can be performed by any imaging technique now known or later developed that is relevant to the medical field. In certain embodiments, the imaging can be performed by hybrid scanning, utilizing functional imaging modalities, such as single photon emission computed tomography (SPECT) or PET, in combination with computed tomography (CT) and / or magnetic resonance imaging (MRI) techniques and combinations thereof. Ultrasound imaging can also be used. Since the conjugates described herein can be used to label bone cancer cells (by binding, for example, to hydroxyapatite), the methods described herein can be used to observe, characterize, monitor, and promote the treatment of bone cancer or other diseases.

[0152] When the subject's bones are imaged (either in connection with the method or not), the method may further comprise diagnosing whether the subject has cancer.

[0153] When the subject has received cancer treatment and the subject's bones are imaged, the method may also include evaluating or monitoring the therapeutic efficacy. For example, the conjugate and / or pharmaceutical composition can be used to quantitatively monitor the growth and proliferation of tumors or lesions in vivo. In certain embodiments, a method for monitoring the progression of cancer (e.g., bone cancer) in a subject is provided, comprising administering a conjugate, a pharmaceutically acceptable salt thereof, or a pharmaceutical composition comprising the conjugate or a pharmaceutically acceptable salt thereof to the subject. This method may also include imaging the subject's cancer (and / or bones).

[0154] During the treatment process, the subject's bones can be imaged regularly, and the doctor can then compare the images and / or otherwise quantify the lesions or cancer growths on the bones to determine the effectiveness of the treatment (e.g., whether there is a differential killing effect on cancer cells during the treatment process, or whether the size of the lesions or cancer growths on the bones is relatively severe). Therefore, a method for determining the likelihood of treatment success for a subject is provided.

[0155] Also provided is a method of binding a conjugate or a pharmaceutically acceptable salt thereof to hydroxyapatite (e.g., in damaged or diseased bone) in a subject (e.g., a subject in need thereof), the method comprising administering to the subject an effective amount of: (i) any conjugate described herein or a pharmaceutically acceptable salt thereof; or (ii) a pharmaceutical composition described herein. In certain embodiments, the conjugate or a pharmaceutically acceptable salt thereof has the following formula: HB-L A -A(Formula I) wherein HB is a group of (eg, linear or branched) anionic ligands, acidic ligands and / or electrolyte ligands (eg, binding to hydroxyapatite); A is an active agent, including a radioactive imaging agent, a radiosensitizer, a radioprotectant or a radiotherapeutic agent; L A is a linker that binds HB and A, or is absent. In certain embodiments, the conjugate or a pharmaceutically acceptable salt thereof has the following formula: HB-A (Formula IA) or a pharmaceutically acceptable salt thereof, wherein HB is a group of anionic ligands, acidic ligands and / or electrolyte ligands (eg, binding to hydroxyapatite); and A is an active agent, including a radioimaging agent, a radiosensitizer, a radioprotectant or a radiotherapeutic agent. In some embodiments, HB binds to hydroxyapatite of damaged or diseased bones. In some embodiments, the subject suffers from bone disease, bone injury or bone disorder (e.g., a disease, disorder or injury described herein). In certain embodiments, the subject suffers from cancer (e.g., bone cancer). In some embodiments, the subject suffers from osteoblastic bone cancer. In some embodiments, the subject suffers from osteolytic bone cancer.

[0156] The conjugates and pharmaceutical compositions may be administered in unit dosage forms and / or compositions.

[0157] For the methods described herein, the conjugates and compositions can be administered in a single dose, or in a combination of multiple doses, which can be administered simultaneously, simultaneously, sequentially or separately in any suitable manner. If the doses are administered in separate dosage forms, the number of doses administered per day for each compound or composition can be the same or different. The conjugate and / or composition doses can be administered by the same or different routes of administration. The conjugate or composition can be administered simultaneously in divided or single form, at the same or different times during the course of treatment, according to a simultaneous or alternating regimen.

[0158] Dosages may vary and may be administered in one or more doses per day for one or more days. Guidance on appropriate dosages for a given class of drug is available in the literature. In various other aspects, the formulation may be administered in a "prophylactically effective amount" (i.e., an amount effective to prevent a disease or condition).

[0159] The conjugate / composition can be administered more than once, for example daily (1-3 times a day or more; qd (once a day), bid (twice a day), tid (three times a day)), weekly (including 1-3 times a day or more), biweekly (including 1-3 times a day or more), monthly (including 1-3 times a day or more), or bimonthly (including 1-3 times a day or more). In each case, it is understood that the effective amount described herein corresponds to the case of administration, or to the total daily, weekly, monthly or quarterly dose determined by the dosing regimen.

[0160] Some definitions

[0161] As used herein, the following terms and phrases shall have the following meanings. Unless otherwise defined, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art.

[0162] The term "about" can allow for a certain degree of variability in a value or range, for example, within 10%, 5%, or 1% of a specified value or a specified extreme value of a range. The term "substantially" can allow for a certain degree of variability in a value or range, for example, within 90%, 95%, 99%, 99.5%, 99.9%, 99.99%, or at least about 99.999% or more of a specified value or a specified extreme value of a range.

[0163] Unless the context clearly dictates otherwise, the terms "a", "an" or "the" are used to include one or more than one. Unless otherwise stated, the term "or" is used to refer to a non-exclusive "or".

[0164] The term "pharmaceutically acceptable carrier" is art-recognized and refers to a pharmaceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, solvent, or encapsulating material, involved in carrying or transporting any subject composition or its components. Each carrier must be "acceptable" in the sense of being compatible with the subject composition and its components and not harmful to the patient. Some examples of materials that can be used as pharmaceutically acceptable carriers include: (1) sugars, such as lactose, glucose, and sucrose; (2) starches, such as corn starch and potato starch; (3) cellulose and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; (4) tragacanth powder; (5) malt; (6) gelatin; (7) talc; (8) excipients, such as cocoa butter and suppository wax; (9) oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil, and tantalum. soybean oil; (10) glycols such as propylene glycol; (11) polyols such as glycerol, sorbitol, mannitol and polyethylene glycol; (12) esters such as ethyl oleate and ethyl laurate; (13) agar; (14) buffers such as magnesium hydroxide and aluminum hydroxide; (15) alginic acid; (16) pyrogen-free water; (17) isotonic saline; (18) Ringer's solution; (19) ethanol; (20) phosphate buffer solution; and (21) other nontoxic compatible substances used in pharmaceutical formulations.

[0165] The terms "patient" and "subject" are used interchangeably and include human patients, laboratory animals (e.g., rodents (e.g., mice, rats, or hamsters), rabbits, monkeys, chimpanzees), livestock (e.g., dogs, cats, or rabbits), agricultural animals (e.g., cattle, horses, pigs, sheep, or goats), or captive wild animals (e.g., bears, pandas, lions, tigers, leopards, elephants, zebras, giraffes, gorillas, dolphins, or whales). The patient to be treated is preferably a mammal, particularly a human.

[0166] Although the concepts of the present disclosure are shown and described in detail in the drawings and descriptions herein, the results in the drawings and descriptions thereof should be regarded as illustrative rather than restrictive; it should be understood that only exemplary embodiments are shown and described, and all changes and modifications that are consistent with the spirit of the present disclosure should be protected. In fact, many specific details are provided to provide a comprehensive understanding of the present disclosure.

[0167] The use of any section headings is intended to aid reading of the document and should not be construed as limiting. In addition, the information associated with a section heading may appear within or outside of that particular section.

[0168] All patents, patent application publications, journal articles, textbooks, and other publications mentioned in the specification are indicative of the level of skill of those skilled in the art to which the present disclosure pertains. All of these publications are incorporated herein by reference to the same extent as if each publication was specifically and individually indicated to be incorporated by reference. In the event of an inconsistency between the usages of this document and those documents incorporated by reference, the usages in the incorporated references shall be deemed supplementary to the usages of this document; for irreconcilable inconsistencies, the usages in this document shall prevail.

[0169] Various techniques and mechanisms of the present disclosure will sometimes describe a connection or link between two components. Similar terms such as attached, linked, coupled, connected, tethered, and inflected forms may be used interchangeably unless noted or otherwise clearly distinguished from the context. These words and expressions do not necessarily indicate a direct connection, but rather include connections through intermediate components. It should be noted that a connection between two components does not necessarily mean a direct, unimpeded connection, as various other components may exist between the two components of interest. Therefore, unless otherwise stated, a connection does not necessarily mean a direct, unimpeded connection. Example

[0170] The following examples are used to illustrate the present disclosure. These examples are not intended to limit the scope of the claimed invention in any way. Example 1 Animal models

[0171] Female Balb / C mice (5-16 weeks old) were purchased from Charles River or The Jackson Laboratory. Subjects received 4T1 (mouse breast cancer cells) (4T1 / L) transfected with luciferase in their femur or tibia. First, the skin at the joint between the femur and tibia was cut. Next, a 26G needle was used to push the tendon connecting the femur and tibia aside, and the same needle was used to drill a hole at the top of the tibia or femur (the location of the growth plate). The 26G needle was removed and a 27G needle attached to a syringe was inserted into the hole formed by the 26G needle to inject 1,000 to 100,000 4T1 / L cells into the bone. Finally, the incision site was sutured.

[0172] Three days after the initial tumor attack, the mice received an intraperitoneal injection of 100 μL of luciferin (15 mg / mL) dissolved in PBS. 15 minutes after injection, the mice were anesthetized and placed in the AMI small animal luminescence and fluorescence imaging instrument to measure and observe luciferin bioluminescence. Luciferin bioluminescence can visually confirm the development and progression of tumors. Figure 1 Shown is luciferin bioluminescence of a tumor growing in the right femur of the first mouse two weeks after the initial tumor challenge.

[0173] After confirming tumor development, mice were imaged using micro-CT to track bone degeneration. The mice were anesthetized and then placed on a micro-CT bed. Their left and right tibiae and femurs were then scanned and the images reconstructed to get a 3D image of their skeleton. Figure 2 Shown are micro-CT images of the right tibia of mice two weeks after initial tumor challenge, demonstrating severe bone resorption resulting from tumor growth. Example 2 Synthesis of fluorescent imaging conjugates

[0174] On 2-chlorotrityl resin, D-aspartic acid was loaded by reacting 1 equivalent of resin with 5 equivalents of Fmoc-D-Asp (tert-butyl)-OH and 15 equivalents of N, N-diisopropylethylamine (DIPEA) in dichloromethane (DCM) for 4 hours. Next, the resin was capped by reacting the resin with 17:2:1 DCM:MeOH:DIPEA for 15 minutes three times. After loading, the resin was sent to the AAPPTEC automatic peptide synthesizer, and 9 D-aspartic acid and 1 cysteine ​​were coupled to synthesize 10D-aspartic acid and 1 cysteine ​​peptide (DD10-C). In short, the peptide was synthesized by Fmoc deprotection on the last amino acid amine attached to the resin, pre-activating the subsequent amino acid with 5 equivalents of PyBop and 15 equivalents of NMM or HBTU, and reacting the resin with the pre-activated amino acid for 40 minutes. Each amino acid coupling was repeated twice to ensure the maximum yield of the final peptide. The Fmoc protecting group on the terminal cysteine ​​amine was not deprotected to serve as an albumin binder and UV active group to facilitate subsequent purification of the conjugate. After completion of the synthesis, DD10-C was deprotected and cleaved from the resin by reacting the DD10-C attached resin with 95% TFA, 2.5% TIPS, 2.5% distilled H2O and 10 mM TCEP at room temperature (RT) for 2 hours. The peptide was precipitated by saturating the collected cleavage solution with ether. The precipitate was purified using HPLC by a 5-50% ammonium acetate buffer (pH=5, 20 mM): acetonitrile method.

[0175] The near-infrared dye S0456 conjugate was prepared by first reacting 1 equivalent of N-Boc-tyramine with 1 equivalent of S0456 and 5 equivalents of CsCO3 in DMSO at room temperature for 4 hours. The conjugate was precipitated by saturated reaction with ethyl acetate, and the Boc protecting group was deprotected by reacting N-Boc-tyramine-S0456 with 40% TFA in DCM for 40 minutes. The conjugate was purified by HPLC by a 5-60% ammonium acetate buffer (pH=7, 20mM): acetonitrile method. Purified tyramine-S0456 was conjugated to 3-maleimidopropionic acid (3MPA) by reacting 1 equivalent of tyramine-S0456 with 1 equivalent of 3MPA (pre-activated with 1 equivalent of PyBOP and 5 equivalents of DIPEA). The reaction was carried out for 4 hours at room temperature. The final 3MPA-tyramine-S0456 was purified and collected by HPLC using 5-60% ammonium acetate buffer (pH=7, 20 mM): acetonitrile.

[0176] Finally, 3MPA-tyramine-S0456 was coupled to DD10-Cys by reacting 1 equivalent of each reactant in anhydrous DMSO for 4 hours at room temperature. The final fluorescent S0456-C-DD10 ( Figure 4 ). Example 3 Fluorescence imaging

[0177] After confirming the development of tumors and bone lesions, the targeting of the hydroxyapatite binding moiety DD10 (or polyaspartic acid peptide) was tested. The subjects in Example 1 received a subcutaneous injection of S0456-C-DD10 (4nmol / 100μL). 24 hours after injection, the mice were anesthetized and placed in the AMI small animal luminescence and fluorescence imaging instrument to observe the localization of the fluorescent conjugate. Figure 3 Shown is the fluorescence of the bone-targeted conjugate in the right femur of the first mouse two weeks after the initial tumor challenge. Example 4 Radioimaging and radiotherapeutic conjugate synthesis

[0178] Lysine was loaded on 2-chlorotrityl resin by reacting 1 equivalent of resin with 5 equivalents of Fmoc-Lys(Alloc)-OH and 15 equivalents of DIPEA in DCM for 4 hours. Next, the resin was capped by reacting the resin with 17:2:1 DCM:MeOH:DIPEA for 15 minutes three times. After loading, the resin was fed into an AAPTEC automated peptide synthesizer to couple 1 phenylalanine and 10 D-aspartic acids to lysine. In brief, the peptides were synthesized by Fmoc deprotection on the last amino acid amine attached to the resin, preactivating the subsequent amino acids with 5 equivalents of PyBop and 15 equivalents of NMM or HBTU, and reacting the resin with the preactivated amino acids for 40 minutes. Each amino acid coupling was repeated twice to ensure maximum yield of the final peptide. At the end of the synthesis, two peptides, K(Alloc)-F-DD10 and K(Alloc)-VMF-DD10, were obtained.

[0179] After the synthesis was completed, alloc was removed from Lys by reacting the resin with 0.1-1 equivalents of tetrakis(triphenylphosphine)palladium(0) and 20 equivalents of phenylsilane in DCM. Deprotection was continued for 40 minutes and repeated twice to obtain KF-DD10 and KVMF-DD10. Next, the resin was washed 3 times with dimethylformamide (DMF), 3 times with sodium diethyldithiocarbamate solution (0.03M, DMF solution), and 3 times with DCM to ensure the removal of palladium. Then, 3 equivalents of DOTA-tri(tert-butyl ester) pre-activated with 3 equivalents of HATU and 10 equivalents of DIPEA were reacted with the resin. The Fmoc protecting group on the terminal D-aspartic acid amine was not deprotected to serve as an albumin binder and UV active group to facilitate purification. Both peptides were deprotected and cleaved from the resin using 95% TFA, 2.5% TIPS, 2.5% distilled H2O and 10mM TCEP at room temperature for 2 hours. The collected cleavage solution was saturated with ether to precipitate the peptide, and the product was purified by HPLC with 5-55% ammonium acetate buffer (pH=5, 20 mM): acetonitrile to obtain K(DOTA)-F-DD10 and K(DOTA)-VMF-DD10 ( Figure 5-7 ). Example 5 Chelation of In-111 to Radioactive Imaging Conjugates

[0180] radioactive isotopes 111 In(100~300μCi) and K(DOTA)-F-DD10( Figure 6 ) and K(DOTA)-VM-DD10( Figure 7 ) of DOTA chelation. Fig.18 Shows the 111 In chelated conjugate K(DOTA)-F-DD10. First, stock solutions of both conjugates were prepared in ultrapure sodium acetate buffer (pH 5, 1 M) at a concentration of 10 mM. 111In reaction, the chelation concentration is 100-300 μCi / 10nmol, and the reaction concentration is at least 1mM. The mixture is reacted at 90°C for 15 minutes, and the chelation efficiency is checked by sending a diluted sample of the mixture to radio HPLC (using 5-95% ultrapure ammonium acetate buffer (pH=5, 20mM): ultrapure acetonitrile method). Next, 5mM of DTPA is added to a final concentration of 0.2mM. DTPA is a chelating agent that can remove any unchelated free radioisotopes. Finally, the mixture is diluted with a PBS solution of 1% DMSO containing 100mg / mL ascorbate and 5mg / mL methionine to a final concentration of 10nmol / 100μL of the conjugate. Ascorbic acid and methionine are both radioactive stabilizers that help prevent the conjugate from being degraded by radioisotopes. Example 6 Radioactive imaging

[0181] Female Balb / C mice (5 to 8 weeks old) bearing intratibial 4T1 / L mouse mammary tumors were treated with 111 A single tail vein injection of In-chelated K(DOTA)-F-DD10 (or K(DOTA)-VM-DD10) was performed at a dose of 100-300 μCi / 10 nmol. The biodistribution of the radiochelated conjugate was observed using a single photon emission computed tomography (SPECT) / computed tomography (CT) instrument at 1 hour, 4 hours, 12 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours and 120 hours after injection. Their body weight was measured every day. One week after the initial injection of the radioactive imaging agent, the mice were subjected to luciferin bioluminescence imaging every other day to track the growth and / or reduction of tumors. In addition, the mice were scanned once or twice a week with micro-CT to monitor bone degeneration and / or formation. After the study, the mice were euthanized and their organs were collected and fixed for histology or any other further analysis.

[0182] Figure 8 Shown are SPECT / CT images of mice bearing tibial tumors injected with In-111 chelated K(DOTA)-F-DD10 (220 μCi injected at a dose of 200 μCi / 10 nmol). Arrows indicate the site of tumor growth and white boxes indicate kidneys.

[0183] Fig. 9 Shown are SPECT / CT images of mice bearing tibial tumors injected with In-111 chelated K(DOTA)-VMF-DD10 (375 μCi injected at a dose of 300 μCi / 10 nmol). Arrows indicate the site of tumor growth and white boxes indicate kidneys.

[0184] Fig.10 Shows the injection 111 In-chelated K(DOTA)-F-DD10 (200 μCi / 10 doses of 160 μCi) or 111 SPECT / CT images of healthy mice treated with In-chelated K(DOTA)-VMF-DD10 (350 μCi at a dose of 300 μCi / 10 nmol). White boxes indicate kidneys.

[0185] In all images, ectopic positioning of the joints (especially the shoulder and between the femur and tibia) can be seen due to the age of the subjects. Mice aged 4 to 12 weeks are considered immature, at this age their growth plates have not yet fully closed, and hydroxyapatite is exposed due to the rapid overbuilding of bones and joints. Example 7 Chelation of radiotherapeutic conjugates by Lu-177

[0186] For chelation, 1 to 6 mCi of radioisotope 177 Lu chelated to K(DOTA)-F-DD10( Figure 6 )'s DOTA. Fig.17 Shows the 177 Lu-chelated conjugate K(DOTA)-F-DD10. First, a stock solution of the conjugate was prepared in ultrapure sodium acetate buffer (pH 5, 1M) at a concentration of 10 mM. The conjugate was then reacted with 177-Lu to a chelation concentration of 1 to 6 mCi / 10 nmol and a reaction concentration of at least 1 mM. The mixture was reacted at 90°C for 15 minutes, and the chelation efficiency was checked by submitting a diluted sample of the mixture to radioactive HPLC (using 5-95% ultrapure ammonium acetate buffer (pH = 5, 20 mM): ultrapure acetonitrile method). Next, 5 mM of DTPA was added to a final concentration of 0.2 mM. DTPA is a chelating agent that can remove any unchelated, free radioactive isotopes. Finally, the mixture was diluted with a PBS solution of 1% DMSO containing 100 mg / mL ascorbate and 5 mg / mL methionine to a final concentration of 10 nmol / 100 μL of the conjugate. Ascorbic acid and methionine are both radioactive stabilizers that help prevent the conjugate from degradation by the radioisotope. Example 8 Radiation therapy

[0187] Female Balb / C mice (14 to 16 weeks old) bearing intratibial 4T1 / L mouse mammary tumors received a single tail vein injection of Lu-111 chelated K(DOTA)-F-DD10 or K(DOTA)-VM-DD10 at a dose of 1 to 6 mCi / 10 nmol. SPECT / CT instrumentation was used to observe the biodistribution of the radiochelated conjugate from 2 to 240 hours after injection. Their body weight was measured every day. One week after the initial injection of the radioactive imaging agent, the mice were subjected to fluorescein bioluminescence imaging every other day to track tumor growth and / or reduction. In addition, the mice were scanned once or twice a week with micro-CT to monitor bone degeneration and / or formation. At the end of the study, the mice were euthanized and their organs were collected and fixed for histology or any other further analysis.

[0188] Fig.11 Shown are SPECT / CT images of mice bearing tibial tumors injected with Lu-177 chelated K(DOTA)-F-DD10 (0.962 mCi at a dose of 1.5 mCi / 10 nmol). Arrows indicate the site of tumor growth and white boxes indicate kidneys. From left to right: images taken 3 hours, 24 hours, 48 ​​hours, 72 hours, 96 hours, 120 hours, and 168 hours after injection of the radiotherapeutic agent. Fig.12 Shown are SPECT / CT images of mice bearing tibial tumors injected with Lu-177 chelated K(DOTA)-F-DD10 (3.0 mCi injected at a dose of 3.0 mCi / 10 nmol). Arrows indicate the site of tumor growth and white boxes indicate kidneys. From left to right: images were taken 3 hours, 24 hours, 72 hours, 96 hours, 120 hours, and 168 hours after injection of the radiotherapeutic agent. Fig.13 SPECT / CT images of mice bearing tibia tumors injected with Lu-177 chelated K(DOTA)-F-DD10 (3.57 mCi at a dose of 3.0 mCi / 10 nmol) are shown. Arrows indicate the site of tumor growth and white boxes indicate kidneys. Top row from left to right: images at 2 hours, 12 hours, 24 hours, and 48 hours after injection of the radiotherapeutic agent. Bottom row from left to right: images at 72 hours, 96 hours, 144 hours, and 196 hours after injection of the radiotherapeutic agent. Fig.14 SPECT / CT images of mice bearing tibial tumors injected with Lu-177 chelated K(DOTA)-F-DD10 (5.50 mCi injected at a dose of 6.0 mCi / 10 nmol) are shown. Arrows indicate the site of tumor growth and white boxes indicate kidneys. Top row from left to right: images at 2 hours, 12 hours, 48 ​​hours, 48 ​​hours, and 72 hours after injection of the radiotherapeutic agent. Bottom row from left to right: images at 96 hours, 144 hours, 196 hours, and 240 hours after injection of the radiotherapeutic agent.

[0189] In all images, minimal ectopic localization was observed because the mice were at least 12 weeks old and older. At this age, mice are considered skeletally mature and their growth plates are mostly or completely closed.

[0190] All polyaspartic acid conjugates S0456-C-DD10, K(DOTA)-F-DD10 and K(DOTA)-VMF-DD10 showed specific localization of tumor-induced bone lesions. After injection, the conjugates adhered to bone lesions for at least 7 days. Ectopic localization was observed in the kidneys, but both conjugates were cleared quickly. Most of the KDFDD10 was cleared from the kidneys within 24-48 hours, while most of the KDVMFDD10 was cleared within 48-72 hours. Compared with KDVMFDD10, KDFDD10 showed faster renal clearance. Ectopic localization was observed in the joints, but this was expected because the mice were young (i.e., 5-6 weeks old) and their growth plates were still in the development stage. This problem was solved by using older mice (i.e., 12 weeks and above). Example 9 Synthesis of novel radioimaging and radiotherapeutic conjugates

[0191] To test whether a brush border membrane (BBM) peptidase linker (immediate release) could accelerate renal clearance, bone-targeted radioimaging and radiotherapeutic conjugates with a BBM peptidase linker were introduced to attach a bone-targeted acidic peptide to a chelator.

[0192] Lysine was loaded on 2-chlorotrityl chloride resin by reacting 1 equivalent of resin with 5 equivalents of Fmoc-Lys(Alloc)-OH and 15 equivalents of DIPEA in DCM for 4 hours. Next, the resin was capped by reacting it with 17:2:1 DCM:MeOH:DIPEA three times for 15 minutes. After loading, the resin was sent to the AAPTEC automated peptide synthesizer for coupling of Val, Met and chelating agents (e.g., DOTA).

[0193] Briefly, the peptide was synthesized by Fmoc deprotection on the last amino acid amine attached to the resin, preactivating the subsequent amino acids with 5 equivalents of PyBop and 15 equivalents of NMM or HBTU, and reacting the resin with the preactivated amino acids for 40 minutes. Each amino acid coupling was repeated twice to ensure maximum yield of the final peptide. At the end of the synthesis, K(Alloc)-Val-Met-DOTA was obtained.

[0194] D-Aspartic acid was loaded on 2-chlorotrityl chloride resin by reacting 1 equivalent of resin with 5 equivalents of Fmoc-D-Asp(OtBu)-OH and 15 equivalents of DIPEA in DCM for 4 hours. Next, the resin was capped by reacting the resin with 17:2:1 DCM:MeOH:DIPEA for 15 minutes three times. After loading, the resin was fed into an AAPTEC automated peptide synthesizer to couple 9 D-Asp and 1 or more aromatic amino acids, such as Phe. In brief, the peptide was synthesized by Fmoc deprotection on the last amino acid amine attached to the resin, preactivating the subsequent amino acids with 5 equivalents of PyBop and 15 equivalents of NMM or HBTU, and reacting the resin with the preactivated amino acids for 40 minutes. Each amino acid coupling was repeated twice to ensure maximum yield of the final peptide. The peptide was cleaved in a protected form by reacting the resin with 1:1:8 acetic acid:TFE:DCM for 30 minutes. At the end of the synthesis, D-Asp 10 (OtBu)-Phe2-Fmoc.

[0195] After the synthesis was completed, alloc was removed from Lys by reacting the resin with 0.1-1 equivalent of tetrakis(triphenylphosphine)palladium(0) and 20 equivalents of phenylsilane in DCM. The deprotection lasted for 40 minutes and was repeated twice to obtain KVM-DOTA. Next, the resin was washed 3 times with DMF, 3 times with sodium diethyldithiocarbamate solution (0.03M, DMF solution), and 3 times with DCM to ensure the removal of palladium. Then, 1 equivalent of protected D-Asp 10 The (OtBu)-Phe2-Fmoc peptide (preactivated with 3 equivalents of HATU and 10 equivalents of DIPEA) was reacted with the resin. The Fmoc protecting group on the terminal Phe amine was deprotected. The peptide was deprotected and cleaved from the resin using 95% TFA, 2.5% TIPS, 2.5% distilled H2O and 10 mM TCEP at room temperature for 2 hours. The collected cleavage solution was saturated with ether to precipitate the peptide, and the product was purified using HPLC with 5-55% ammonium acetate buffer (pH=5, 20 mM): acetonitrile to give K(DD 10 F2)VM-DOTA( Fig.15 ). Fig.16 The structure of the conjugate is shown.

Claims

1. A conjugate of formula I: HB-L A -A(Formula I) or a pharmaceutically acceptable salt thereof, wherein: HB comprises groups of polyanionic ligands, polyacidic ligands and / or polyelectrolyte ligands that bind to hydroxyapatite; A is an active agent, comprising a radioimaging agent, a radiosensitizer, a radioprotectant, or a radiotherapeutic agent; and L A is a linker that binds HB and A, or is absent.

2. The conjugate according to claim 1, wherein HB comprises a group of a linear polyanionic ligand, a polyacidic ligand and / or a polyelectrolyte ligand that binds to hydroxyapatite. The conjugate according to claim 1 , wherein HB comprises an amino acid or a derivative thereof.

4. The conjugate according to claim 3, wherein HB comprises L-aspartic acid, D-aspartic acid, L-glutamic acid, D-glutamic acid, or a derivative thereof, or a mixture of two or more of the above amino acids or their derivatives.

5. The conjugate according to claim 1, wherein HB further comprises (i) a serum albumin binder (AB) directly conjugated to HB, or (ii) AB and a linker L AB (AB-L AB ), where AB-L AB By L AB Conjugated with HB.

6. The conjugate according to any one of claims 1 to 5, wherein L A , L AB or L A and L AB Both are in L-configuration.

7. The conjugate according to any one of claims 1 to 5, wherein L A , L AB or L A and L AB Both are in D-configuration.

8. The conjugate according to any one of claims 1 to 5, wherein one or more peptide bonds of HB and / or A are arranged in a relative cis orientation.

9. The conjugate according to any one of claims 1 to 5, wherein one or more peptide bonds of HB and / or A are arranged in a relative trans orientation.

10. The conjugate according to any one of claims 1 to 5, wherein HB comprises a linear polyanionic group of formula X-A1, X-A2, X-A3 or X-A4: in: R is COOH for L- or D-aspartic acid, CH2COOH for L- or D-glutamic acid, or CH2CH2COOH for an unnatural acidic amino acid; n = 1-50; Indicates that L A attachment point; and, When HB also contains AB or AB-L AB hour, Indicates AB or L AB attachment point.

11. The conjugate according to any one of claims 1 to 5, wherein L A and L AB Either or both of the compounds may contain a sustained release linker.

12. The conjugate according to any one of claims 1 to 5, wherein L A Contains slow release fitting.

13. The conjugate according to any one of claims 1 to 5, wherein L A Contains quick-release fittings.

14. The conjugate according to claim 1, wherein L A Contains one or more amino acids.

15. The conjugate according to claim 1 or 14, wherein L A Contains brush border membrane (BBM) connector.

16. The conjugate according to claim 1 or 14, wherein L A A BBM linker is included which comprises Met-Val-Lys.

17. The conjugate according to any one of claims 1-5 or 14, wherein L A Contains L1 or L2: in Indicates L A Between A and L A and the attachment point between HB.

18. The conjugate according to any one of claims 1-5 or 14, wherein L A and L AB Either or both of contain a spacer.

19. The conjugate of any one of claims 1-5 or 14, wherein A comprises a chelating agent.

20. The conjugate according to any one of claims 1-5 or 14, wherein A comprises DOTA (1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid) or a derivative thereof.

21. The conjugate of claim 19, wherein the chelator chelates or binds to a radioisotope.

22. The conjugate of claim 21, wherein the radioisotope is a therapeutic radioisotope comprising an alpha emitting radioisotope or a beta emitting radioisotope.

23. The conjugate of claim 22, wherein the beta-emitting radioisotope is 177 Lu.

24. The conjugate of claim 21, wherein the chelator is an imaging radioisotope.

25. The conjugate of claim 24, wherein the imaging radioisotope is a gamma-emitting radioisotope or a positron emission tomography (PET) imaging radioisotope.

26. The conjugate of claim 24 or 25, wherein the imaging radioisotope is a gamma-emitting radioisotope and is 111 In.

27. The conjugate according to claim 1, having the following structure:

28. The conjugate according to claim 1, having the following structure:

29. The conjugate according to claim 1, having the following structure:

30. The conjugate according to claim 1, having the following structure:

31. The conjugate according to claim 1, 177 Lu chelates and has the following structure:

32. The conjugate according to claim 1, 111 In chelate has the following structure:

33. A pharmaceutical composition comprising the conjugate of any one of claims 1-32 and a pharmaceutically acceptable carrier or excipient.

34. The pharmaceutical composition of claim 33, further comprising a radiosensitizer, a radioprotectant, an immunotherapeutic agent, a chemotherapeutic agent, an anticancer agent and / or a hormone therapy agent.

35. A method of imaging and / or treating a subject's skeleton, the method comprising administering to the subject an effective amount of: (i) the conjugate of any one of claims 1 to 32 or a first pharmaceutically acceptable salt thereof; (ii) the first pharmaceutical composition of claim 33 or 34; or (iii) (a) a first pharmaceutical composition of claim 33 or 34, and simultaneously or sequentially, in either order, (b) (i') an active agent, or (ii') a second pharmaceutical composition comprising said active agent and a second pharmaceutically acceptable carrier or excipient.

36. The method of claim 35, wherein the active agent of (b) comprises a radiosensitizer, a radioprotectant, an immunotherapeutic agent, a chemotherapeutic agent, an anticancer drug, or a hormonal therapeutic agent.

37. The method of claim 35 or 36, wherein the active agent of (b) comprises a radioprotectant.

38. The method of any one of claims 35-37, wherein the active agent of (b) comprises lysine.

39. The method of claim 35, wherein the subject has cancer.

40. The method of claim 39, wherein the cancer is primary bone cancer.

41. The method of claim 40, wherein the primary bone cancer is osteosarcoma, chondrosarcoma, Ewing sarcoma, or chordoma.

42. The method of claim 39, wherein the cancer is secondary bone cancer.

43. The method of claim 42, wherein the secondary bone cancer is metastatic breast cancer, prostate cancer, multiple myeloma, thyroid cancer, lung cancer, kidney cancer, ovarian cancer, colon cancer, or melanoma.

44. The method of claim 35, further comprising imaging the subject's skeleton.

45. The method of claim 35 or 44, wherein the subject's bones are imaged and the method further comprises diagnosing whether the subject has cancer.

46. ​​The method of any one of claims 35-45, wherein the subject has been treated for cancer and the subject's skeleton is imaged, and the method further comprises assessing or monitoring the efficacy of the treatment.

47. A method of binding the conjugate of any one of claims 1-32 or a pharmaceutically acceptable salt thereof to hydroxyapatite in a subject, comprising administering to the subject an effective amount of: (i) the conjugate of any one of claims 1-32 or a pharmaceutically acceptable salt thereof; or (ii) the pharmaceutical composition of claim 33 or 34.

48. The method of claim 47, wherein the subject has cancer.

49. The method of claim 48, wherein the subject has bone cancer.

50. The method of claim 48, wherein the subject has osteoblastic bone cancer.

51. The method of claim 48, wherein the subject has osteolytic bone cancer.